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 1.1 Rare Diseases 
 
Rare diseases, including those of genetic origin, are disorders that only affect small 
numbers of individuals in the world. Low prevalence is taken as prevalence of less than 
5 per 10.000 persons in the European Union. The United States definition is very 
similar to the European one. In the US a patience of rare disease is generally considered 
to have a prevalence of fewer than 200.000 affected individuals. Certain diseases with 
200.000 or more affected individuals may qualify if subpopulations of these conditions 
are equal to the prevalence standard for rare diseases. 
However, the low prevalence of this pathologies does not mean that there is a small 
number of patients affected by a rare disease. Only in Italy there are thousands of 
individuals affected by rare diseases and in Europe there are tens of thousands. The 
number of known and diagnosed rare diseases ranges from 7,000 to 8,000. Moreover 
some diseases are widespread in certain parts of the world but rare in others. The topic 
of rare diseases implies necessarily talking about orphan drugs. An orphan medicinal 
product, or "orphan drug", is a product that is potentially useful in treating a rare disease 
but does not have a market sufficient to cover the costs of its development. It therefore 
remains without a sponsor and thus an "orphan". These pharmaceutical products, due to 
the fragmentation of the single pathologies, often fail to arouse the economic interest of 
the pharmaceutical companies and the loss of a single research lab can be devastating 
for affected patients and their families. 
Many rare diseases are caused by changes in genes and are called genetic diseases. A 
genetic disorder is a disease caused by a different form of a gene called a variation, or 
an alteration of a gene called a mutation. Many diseases have a genetic aspect. Some, 
including many cancers, are caused by a mutation in a gene or group of genes in a 
person's cells. These mutations can occur randomly or because of an environmental 
exposure such as cigarette smoke. Other genetic disorders are inherited. A mutated gene 
is passed down through a family and each generation of children can inherit the gene 
that causes the disease. Still other genetic disorders are due to problems with the 
number of packages of genes called chromosomes. In Down syndrome, for example, 
there is an extra copy of chromosome 21.  
There are many different type of rare diseases and different part of the body  can be 
affected: autoimmune disorders, blood disorders, brain and nervous system, cancers, 
chromosome disorders, congenital heart defects, connective tissue disorders, immune 
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 disorders,  kidney and urinary disorders,  leukodystrophy, metabolic disorders, 
mitochondrial diseases, muscles, bones, and joints, skin disorders. In particular, in the 
metabolic disorders have to be mentioned Menkes disease and Wilson's disease which 
are inherited disorders of copper metabolism resulting from the absence or dysfunction 
of homologous copper-transporting ATPases. Also Cytochrome c Oxidase Deficiency is 
a very rare inherited metabolic disorder which is characterized by deficiency of the 
enzyme Cytochrome c Oxidase (CcO). Same cases, as Leigh's disease, imply inherited 
metabolic disorders that damage the central nervous system (brain, spinal cord, and 
optic nerves). Another important disease involving brain and nervous system is the 
Amyotrophic Lateral Sclerosis (ALS) which is a disease that attacks motor neurons that 
control muscles.  
During my PhD I focused my attention on proteins involved in the above mentioned 
rare diseases in order to better understand causes and development of  the disorders. 
 
1.2 Wilson's disease 
 
Wilson disease and Menkes syndrome are human diseases of copper metabolism caused 
by mutations in the genes for two closely related proteins, the Wilson (1) and Menkes 
(2) copper (I)- transporting ATPases. These proteins couple ATP hydrolysis to copper 
translocation across membranes. Menkes syndrome is caused by decreased copper 
uptake across the small intestine as well as impaired copper distribution to a variety of 
tissues, including the brain. By contrast, Wilson disease is characterized primarily by 
copper overload in the liver because of reduced biliary excretion (3). (Fig. 1) 
Wilson’s disease (WD) was first described in 1912 as progressive lenticular 
degeneration by Samuel Alexander Kinnier Wilson. He described WD as a rare, 
familial, progressive, and invariably fatal disease, characterized mainly by neurological 
deficits and liver cirrhosis. WD is an autosomal recessive disorder of copper transport, 
leading to systemic copper accumulation and multi-organ damage, particularly of the 
brain and the liver. Permanent organ damage can be effectively prevented if early de-
coppering treatment is initiated. By the latter criterion, the National Institutes of Health 
listed WD as a rare disease. Most literature describes the worldwide prevalence of WD 
as 1 in 30.000, with a carrier rate of 1 in 90 and incidence ranging from 15 to 30 per 
million (5). 
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Fig. 1 : Simplified scheme of copper  distribution in the body.  
CP indicate Ceruloplasmin.(4) 
 
The conventional diagnosis of WD depends on typical neurological symptoms, the 
presence of Kayser-Fleischer  rings observed by slit-lamp examination and a decreased 
serum ceruloplasmin concentration (6). The disease onset usually occurs in childhood 
and young adulthood. However, case reports in the literature include patients from three 
years of age to 72 years old (7). Clinical manifestations of WD may show considerable 
variation. Typical presentations involve mainly hepatic, neurological, and psychiatric 
manifestations.  
In 1993 the gene responsible for WD was identified (1, 8, 9), and the gene product was 
shown to be the copper(I) P-type adenosine triphosphatase ATP7B (10). Indeed also 
ATP7A (Menkes protein) belong to the group of P-type ATPases  and Wilson protein 
has 67% amino acid identity to the Menkes protein (1) and the same structural 
characteristics. 
The culprit ATP7B gene consists of 21 exons that span a genomic region of about 80 kb 
and encode a protein of 1465 amino acids. Mutant ATP7B results in defective copper 
incorporation into ceruloplasmin and a reduction in biliary excretion of copper. 
Copper(I)-transporting P-Type ATPase ATP7B is expressed primarily in the liver and 
kidney. The protein plays a dual functional role in the hepatocyte (11). First it mediates 
the biosynthesis of holoceruloplasmin by delivering copper to apoceruloplasmin within 
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 the trans-Golgi network under low-copper conditions. The other role is to facilitate 
biliary excretion of excess copper when cellular copper concentrations are elevated. 
Therefore, an ATP7B mutant fails in the process of holoceruloplasmin synthesis and/or 
the biliary excretion of copper, which in turn results in a significant reduction of serum 
ceruloplasmin concentration and an accumulation of copper in the liver, respectively. 
For example, a WD mutant protein, R778L, has been shown to be extensively 
mislocalized, presumably to the endoplasmic reticulum (12). Factors other than ATP7B 
mutations such as COMMD199 may modulate the clinical manifestations, but more 
convincing data are required. Numerous mutational studies of WD have been 
conducted, and they have revealed that the mutation spectrum of the ATP7B gene is 
population specific. The most frequent ATP7B mutation in Caucasian patients is 
H1069Q, which is present in up to 72% of all alleles (13-17). No such mutation has so 
far been detected in East Asian WD patients. The most common East Asian-specific 
mutant is R778L present up to 44% of WD patients (18-22). To date, more than 370 
mutations have been reported worldwide, and most are rare and infrequent 
(www.medicalgenetics.med.ualberta.ca/wilson/index.php)(23). 
 
 
1.2.1 An overview on Wilson Protein 
 
The Wilson disease protein (WND), as Menkes similarly disease protein,  are copper(I)-
transporting  ATPase involved in copper delivery to the secretory pathway of Golgi. It 
is usually localized in the trans-Golgi network (TGN) of hepatocytes where it delivers 
copper to key metalloenzymes, including ceruloplasmin, a multicopper oxidase 
involved in high affinity iron uptake (24, 25). This process is dependent on interaction 
with Atox1(or HAH1) a copper chaperone that delivers Cu(I) ions to WND (26, 27). At 
elevated copper concentrations, WND redistributes to cytoplasmic vesicles and 
mediates copper efflux from the cell (24, 28). Similarly, the Menkes disease protein 
(MNK) relocalizes from the trans-Golgi network to the plasma membrane in response to 
changing copper concentration (29, 30)(Fig.2). This is the mechanism by which the 
copper ingested with the diet is transported by Menkes through the basolateral 
membrane of enterocytes into the portal blood and hence to other tissues. (31) 
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Fig.2: Localization and function of Cu-ATPases in low (green arrows) and high (red 
arrows) copper. In basal (low) copper, the Cu- ATPases are located in the trans-Golgi 
network (TGN) where they deliver copper to secreted copper-dependent enzymes. When 
copper is elevated, the Cu-ATPases relocate to vesicles. The Cu-ATPase in the vesicles 
may or may not be active, depending on the intravesicular copper concentration. The 
copper-containing vesicles are then delivered to the plasma membrane where the 
accumulated copper is released and the Cu-ATPase is endocytosed. Apo-Atox1 removes 
regulatory copper from the NH2-terminal domain and thus may facilitate return of the 
ATPase to the TGN. (4) 
 
 
 
At the biochemical level, the function of Cu-ATPases is to translocate copper across the 
membrane from the cytosol into the lumen of appropriate intracellular compartment 
(either TGN or vesicles). The vectorial copper translocation across the membranes is 
driven by the hydrolysis of ATP and two copper ions are transported per one 
hydrolyzed ATP. Both ATP7A and ATP7B belong to the P1B-subfamily of the P-type 
ATPases which are a superfamily of membrane proteins  responsible for the active 
transport of a variety of cations across cell membranes. This subgroup contains over 
100 members (see http://www.patbase.kvl.dk/IB.html) and is characterized by a number 
of transmembrane helices involved in the formation of an intramembranous channel; by 
an hydrophilic region protruding into the cytosol, which contains the Actuator domain 
(A-domain) and the ATP-binding domain, which in turn can be further separated into 
two smaller domains named Phosphorylation domain (P-domain) and Nucleotide-
binding domain (N-domain); and by the presence of six soluble metal-binding domains 
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 (MBDs) at the N- and/or C-termini of the molecule, as well as characteristic conserved 
sequence motifs GMXCXXC through which it can bind one equivalent of copper (32). 
The number of the N-terminal metal binding domains (NMBDs) varies from one in 
bacteria and archea to six in higher eukaryote ATPases (33). The N-terminal copper-
binding cytosolic tails of ATP7A and ATP7B are both ca. 630 amino acids long.  
Moreover all the protein belonging to the P1B-subfamily show some peculiar features: 
(i) heavy-metal binding sites in the polar amino-terminal region; (ii) a conserved 
intramembranous Cys-Pro-Cys, Cys-Pro-His or Cys-Pro-Ser motif (hereafter CPx 
motif); (iii) a conserved histidine-proline dipeptide (HP locus) 34 to 43 amino acids 
carboxy-terminal to the CPx motif; and (iv) a unique number and topology of 
transmembrane helices. 
Similarly to all members of the P-type ATPase family, so-called because they catalyze 
self phosphorylation of a key conserved aspartate residue within the protein,  the human 
Cu-ATPases hydrolyze ATP with the formation of a transient acyl-phosphate 
intermediate (Fig. 3) Phosphorylation takes place at the invariant Asp residue in the 
signature motif DKTG (Fig. 3a). The reaction requires the transfer of copper from the 
cytosol to the intra-membrane portion of the transporter; while the release of copper to 
the opposite side of the membrane is accompanied by dephosphorylation (34, 35). Cu-
ATPases can also be phosphorylated by inorganic phosphate at the same aspartate 
residue within the DKTG motif. This reaction is reverse to the dephosphorylation step 
and is inhibited by copper binding to the intra-membrane site(s) from the luminal milieu 
(36). Comparing the ability of Cu-ATPase to be phosphorylated from ATP or Pi and the 
effect of copper on this reaction may serve as a tool for determining the conformational 
state of the enzyme. During the catalytic cycle the Cu-ATPases are likely to undergo 
significant conformational changes(35). By analogy with other P-type ATPases, the 
binding of copper from the cytosolic side is thought to take place when the protein is 
present in the so-called E1 state, which is characterized by high affinity of the intra-
membrane sites for the transported ion. Both transmembrane binding sites bind 
copper(I) with high affinity (Ka1=1.12  ± 0.25 fM-1 and Ka2=1.30 ± 0.22 fM-1) (37, 38). 
Copper binding to the intra-membrane sites is associated with the transfer of c-
phosphate of ATP to the Cu-ATPase and transient stabilization of the phosphorylated 
state of the protein, E1P (Fig. 3b).  
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Fig. 3: Transmembrane organization and catalytic cycle of human Cu-ATPases. (a) 
Cartoon illustrating the major functional domains of Cu-ATPases. The N-terminal 
domain contains six copper-binding MBDs (MBD1–6). The transmembrane portion has 
eight transmembrane segmants (TMS); the position of residues predicted to be involved 
in copper coordination (CPC, YN, and MxxS) is indicated. The A-domain may link 
changes in the N-terminal domain with those in the ATPbinding domain and in the 
transmembrane portion. The ATP-binding domain consists of the P-domain and the N-
domain. The domains of ATP7B for which structure has been experimentally 
determined are indicated by dashed circles and corresponding structures are shown. 
Two Leu residues in the C-terminal tails required for endocytosis and/or return to TGN 
are indicated by ‘‘LL’’. (b) The simplified catalytic cycle of human Cu-ATPases. Two 
major conformational states associated with high affinity for ATP and Cu (E1) and 
lower affinity for these ligands (E2) as well as phosphorylated intermediates (E1–Pi–Cu 
and E2–Pi–Cu) are shown (4). 
 
In this state, access to intra-membrane sites from the cytosol is blocked and copper is 
sequestered in the ‘‘occluded’’ form. Subsequently, the Cu-ATPase undergoes 
conformational change to the E2P state, and the affinity for copper is decreased. It is 
thought that in this state copper is released from the transporter and is taken up by an 
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 acceptor protein. Intermediate proteins are not required for copper transfer from the 
transporter to acceptors (39), however interaction between ATP7A and SOD3, a 
putative target protein of ATP7A activity, has been reported (40). This latter 
observation suggests that the donor–acceptor interaction, although not obligatory, may 
facilitate metal transfer to the copper-requiring enzymes in the secretory pathway. After 
copper is released, the Cu-ATPase dephosphorylates (E2 state) and then undergoes 
conformational transition into a high-affinity state, E1, for initiation of the next 
transport cycle.  
Both WND and MNK ATPases consist of eight transmembrane helices, of which the 
sixth contains an invariant CPC motif proposed to bind metal ions. Phosphatase- and 
ATP-binding domains and a phosphorylation site are conserved as well (41). P1B-type 
transport ATPases are distinguished from other P-type ATPases by the presence of 
multiple soluble N-terminal domains containing a conserved CXXC metal-binding 
motif (42). 
Both WND and MNK contain six soluble domains, whereas the yeast homolog, Ccc2 
(43), contains only two repeats and the Drosophila melanogaster homolog contains four. 
These domains are present not only in the copper ATPases but also occur in Zn(II), 
Cd(II), and Pb(II) transporters (41, 42). The Atox1 (HAH1) metallochaperone and its 
homologs, both eukaryotic and prokaryotic, contain a single CXXC motif (44). Crystal 
and solution structures of Atox1(45), yeast Atx1(46, 47), bacterial CopZ(48, 49), and 
single domains of MNK(50) and Ccc2(51) reveal a conserved βαββαβ-fold with the 
cysteines from the CXXC motif coordinating metal ions on a surface-exposed loop. 
Notably, the CXXC motifs from two Atox1 molecules coordinate a single Cu(I) ion in 
the x-ray structure (45). Both the WND and MNK N termini bind 5–6 copper ions (52), 
and x-ray absorption spectroscopic studies indicate that the copper is present as Cu(I), 
ligated by the sulfurs from two cysteines (53-55). The roles of the six WND and MNK 
metal-binding domains in copper metabolism are not well established. Numerous 
genetic and biochemical studies suggest that the domains are not functionally 
equivalent. For  WND,  introduction of wild type or mutated ATP7B cDNA into a yeast 
strain lacking the CCC2 gene , the yeast homologue of ATP7B, indicate that the sixth 
domain alone is sufficient for copper loading of Fet3, the yeast homolog of 
ceruloplasmin (56, 57). Furthermore, the second or third metal-binding domain cannot 
substitute for the sixth domain, supporting distinct functions for the individual domains 
(57). Then, a more specific function has been assigned to domains 5 and 6. These 
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 domains are responsible for the cooperative effect of copper on WND catalytic 
phosphorylation activity and human missense mutations found within MBD1, 5, and 6 
of WND are known to give rise to Wilson disease, and these mutants show impaired 
interaction with HAH1 (58). In contrast to WND, yeast complementation studies on 
MNK indicate that the first four N-terminal domains are important for copper transport 
(59). It may be that the domains function is different in the two ATPases. Another 
potential function for the metalbinding domains is mediating copper-responsive cellular 
relocalization.  
The six soluble domains of both WND and MNK receive copper from the cytoplasmatic 
metallochaperone HAH1. The KCu binding affinity of the six MBDs of both theMNK 
(60-62) andWLN (63, 64) proteins range between 1- and 5-fold the binding affinity of 
the copper(I) metallochaperone HAH1.  The exact role and interplay of the six domains 
is still unclear. In the case of MNK protein, the six-soluble domains interact differently 
with HAH1. The interactions have been investigated by a variety of techniques  ranging 
from yeast-two hybrid assays to NMR(62, 65-68). These data indicate that the MNK 
first and fourth domains form a metal-mediated adduct with HAH1, whereas the six 
domain is simultaneously loaded with copper without formation of  adduct. In case of 
WND is not still clear the behaviour of the  six MBD. A pathway was proposed for 
copper delivery to the N-terminal MBDs of WND from an NMR study of MBD5-6: 
Cu(I)HAH1 forms a complex with MBD4 and MBD2 that allows transfer of copper 
between these partners, while any complex formation and no copper transfer occur 
between Cu(I)HAH1and MBD5–6  suggesting that WLN5–6 must acquire copper from 
one of the other metal-binding (69). Another study suppose that MBD3-4 have similar 
affinities for incorporation of Cu(I) from HAH1, even if Cu(I) HAH1 forms detectable 
amounts of a macromolecular complex with domain 4, whereas domain 3 removes 
Cu(I) from the metallochaperone without detectable complex formation (70). Domains 
1–4 of WND have also been proposed to function in copper-responsive localization (57, 
58). Anyway all that study were done studing the interaction of HAH1 with single 
domains. For this reason, during my PhD I focus my work to obtain the whole 633 
residues-long N-terminal tail of WND in order to study simultaneously the behaviour of 
all six MBD in presence of Cu(I) and Cu(I)-HAH1 complex. 
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 1.3 Cytochrome c Oxidase Deficiency 
 
Mitochondria, ubiquitous organelles of eukaryotic cells, are the main generators  of 
cellular ATP and carry several important metabolic reactions. Mitochondria also play an 
active role in survival, death signalling and cellular calcium homeostasis. Defects in 
mitochondrial function are associated with numerous neurodegenerative diseases 
(Parkinson's, Alzheimer's and Huntington's disease) and, in particular, with 
mitochondrial diseases. Mitochondria have their own genome which encodes for about 
1% of the total mitochondrial proteins, therefore, mitochondrial biogenesis occurs as a 
result of a highly coordinated action between the nuclear and the mitochondrial genome 
that requires the import of several proteins into the mitochondria that are encoded by the 
nuclear genome (71). For this reason, mitochondrial diseases are caused by mutations in 
mitochondrial genes, in nuclear genes encoding for subunits of the respiratory chain 
complexes or in genes coding for proteins involved in the nuclear–mitochondrial 
communication (72). 
The mitochondrial respiratory chain is composed of five multisubunit enzymes whose 
components are encoded in both the nuclear and mitochondrial genomes; of the 82 
structural subunits, only 13 are encoded in mtDNA. In addition to the structural 
components of the respiratory chain, a large number of proteins are involved in the 
assembly and maintenance of the enzyme complexes. Fully half of the known 
mitochondrial proteins in the yeast S.cerevisiae are involved in some aspect of 
mitochondrial biogenesis (73), and more than 30 different genetic complementation 
groups have been identified for the assembly of Cytochrome c Oxidase (CcO) alone 
(74). More than 50 different pathogenic mutations have been identified in mitochondrial 
DNA (mtDNA)(75), and much attention has now focused on identification of the 
nuclear gene defects associated with respiratory chain deficiency. 
CcO is the terminal electron acceptor of the mitochondrial respiratory chain. It is a 
membrane-bound redox-driven proton pump (76) located in the inner mitochondrial 
membrane, where it catalyzes reduction of molecular oxygen to water and pumps 
protons across the membrane (77). In this process a membrane electrochemical proton 
gradient is generated; the energy stored by the proton gradient is subsequently utilized 
for ATP synthesis. The reduction of O2 to H2O in the catalytic centre of CcO generates 
energy that is necessary for proton translocation from the mitochondrial matrix (a region 
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 of low proton concentration and negative electrical potential) to the intermembrane 
space (which is in contact with the cytosol, a region of high proton concentration and 
positive electrical potential). Mammalian CcO consists of 13 polypeptide subunits, 3 of 
which (COX1-COX3) are encoded by the mitochondrial genome with the remaining 10 
subunits encoded by the nuclear genome (78, 79). In addition to the subunits, over 30 
distinct proteins are important for the assembly of CcO (74). A number of these 
accessory proteins are important in the processing and translation of COX1-COX3 
mRNA transcripts, in chaperoning the assembly process, and in the synthesis or 
delivery of cofactors. The cofactors in CcO include two copper sites (CuA and CuB), 
two heme-a moieties, a magnesium and zinc a ion (80)(Fig.4 and Fig.5). 
 
 
a b
 
 
 
Fig. 4: The structure of bovine CcO is shown with the 13 subunits colored differently 
(a). The cofactors are largely obscured by the polypeptide chains. Panel b shows the 
cofactors (81). 
 
Little is known about the delivery of Zn and Mg ions to the mitochondrion or whether 
specific accessory factors are necessary for the insertion of  these ions  into CcO. More 
information are available concerning copper delivery and insertion into CcO. A total of 
three copper ions have to be inserted into two subunits COX1 and COX2 which contain 
the CuB and the CuA centers, respectively.  
The former has one copper ion buried 13Å below the membrane surface (Fig.5), while 
the second contains a binuclear copper site located into the inner membrane space of the 
mitochondria in eukaryotes. 
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Fig.5: Structural representation of the mitochondrial-encoded subunits that make up the 
catalytic core of the enzyme, COX1 (yellow), COX2 (blue) and COX3 (grey)within their 
cofactors (81).  
 
 
Because both COX1 and COX2 subunits of CcO are synthesized inside the 
mitochondria, the three Cu atoms must be imported from the cytoplasm. COX1 and 
COX2 are metallated by a pathway that consists of COX17 and the cochaperones, 
SCO1, SCO2 and COX11. COX17 delivers copper to COX11 for subsequent insertion 
into the CuB site in COX1, and to SCO1 for insertion into the CuA site of COX2 
(Fig.6). 
CcO deficiencies in humans comprehend a wide variety of disorders and the 
pathological features and genotype have been extensively reviewed (82).  
Genotypically, isolated CcO deficiencies could arise from mutations in any of the 3 
subunits encoded in the mtDNA, from any of the 10 structural subunits encoded in the 
nucleus or from mutations in any of the assembly factors. Phenotypically, all these 
possibilities create a wide variation on the clinical symptoms that could affect single or 
multiple organs.  
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Fig. 6: Scheme of Cu metalation of COX1 and COX2 mediated by COX11 and SCO1, 
respectively. COX17 is postulated to transfer Cu(I) to SCO1 prior to the transfer to the 
CuA site in COX2 and to transfer Cu(I) to COX11 prior to transfer to the buried CuB 
site in COX1(83).  
 
 
Only few CcO deficiencies involve mutations in the mitochondrial encoded subunits 
(84, 85). The clinical presentations of such mutations encompass myopathy, 
sideroblastic anemia, amyotrophic lateral sclerosis (ALS)-like syndrome, 
encephalomyopathy and MELAS (mitochondrial myopathy, encephalopathy, lactic 
acidosis and stroke-like episodes)(72, 86). Mutations in the mtDNA could affect a 
single tissue (myopathies) or multiple systems (MELAS and encephalomyopaties) and 
the severity of the CcO deficiency could vary in different tissues. In terms of defects 
derived from nuclear mutations, the differences in tissue specificity could be explained 
by differences in the levels of certain subunits or assembly factors, presence of specific 
isozymes, specific regulatory mechanisms (phosphorylation and allosteric regulation) or 
by differential availability of cofactors. Mutations in the nuclear-encoded subunits were 
not found for many years in patients with CcO deficiency leading to the idea that these 
mutations were incompatible with live. Recently, Massa and collegues (87) described 
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 two patients (siblings from cousin parents in third degree) suffering from severe 
infantile encephalopathy with CcO deficiency. (Fig. 7) 
 
 
        
 
Fig. 7: Gene defects associated with Cytochrome c Oxidase deficiencies in humans and 
existing animal models. Clinical pathologies associated with mutations in respective 
CcO subunits or assembly factors associated with CcO deficiencies are labeled in red. 
The different animal models created for a corresponding protein or mitochondrial DNA 
are shown in the figure: mouse, zebrafish, Drosophila, and C. elegans.(88) 
 
 
The majority of the genetic defects related to CcO deficiencies have been found in 
nuclear genes coding for auxiliary proteins. The first identified CcO deficiency with a 
nuclear origin was Leigh syndrome (LS) is an autosomal recessive inherited 
neurodegenerative disorder with a characteristic neuropathology consisting of focal, 
bilateral lesions in one or more areas of the central nervous system, including the 
brainstem, thalamus, basal ganglia, cerebellum, and spinal cord. The lesions are areas of 
demyelination, gliosis, necrosis, spongiosis, or capillary proliferation. Clinical 
symptoms depend on which areas of the central nervous system are involved (89).  
LS was originally described as a sub-acute necrotizing encephalopathy which affects 
infants and young children. The estimated prevalence of LS is 2.05 children per 10 000, 
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 while the estimated prevalence for all mitochondrial respiratory chain disorders is 7.5–
8.7 per 10000 (90). Therefore, LS represents one of the most frequent mitochondrial 
disorders in childhood. LS diagnostic criteria include a progressive neurological disease 
with motor and intellectual developmental delay, hypotonia, movement disorders, 
brainstem and/or basal ganglia degeneration and often increased lactate levels in blood 
and/or cerebrospinal fluid (CSF)(91). 
LS patients die between 6 months to 12 years of age. The typical pathology of Leigh 
syndrome includes the presence of bilateral symmetric necrotic lesions in subcortical 
areas of the brain that develop into ophthalmoparesis, nystagmus, ataxia, dystonia and 
optic atrophy (92). The residual levels of CcO activity observed in LS patients range 
from 10 to 25% of control values with no apparent correlations in terms of severity and 
tissue specificity. The majority of CcO-deficient LS is associated with mutations in the 
SURF1 gene (93), located on chromosome 9q34. The gene encodes the SURF1 protein 
that is anchored to the inner mitochondrial membrane by two transmembrane domains 
and is highly conserved in a number of species (94). Although the exact function of 
SURF1 still remains unclear, it is known that it affects CcO assembly. Patients with 
SURF1 mutations show accumulation of early CcO assembly intermediates and marked 
reduction of the fully assembled complex (95). 
However, not all the mutations in this gene produced Leigh syndrome, some SURF1 
patients did not develop the characteristic neurodegenerative lesions. In some cases, the 
pathology of Leigh syndrome has been associated with mutations in the COX10 gene, 
which encodes heme-a:farnesyltransferase, or with mutations in the mtDNA (96). 
Moreover, LS can result from defects in other genes altering energetic metabolism such 
as pyruvate dehydrogenase, NADH:ubiquinone oxidoreductase (complex I) or ATP 
synthase (complex V) (97). A less severe form of LS is the French–Canadian Leigh 
syndrome (FCLS, exclusive of the Charlevoix and Saguenay-Lac-St. Jean region of 
Quebec). Clinical presentations of this form include mild regression of psychomotor 
skills and a fatal lactic acidosis with death occurring between 3 and 10 years of age. In 
this disorder, the tissues mostly affected are brain (basal ganglia) and liver (98). 
LRPPRC (leucine-rich pentatricopeptide repeat cassette) was identified as the gene 
responsible for this disease (99). LRPPRC is a homologue of the yeast P309, another 
CcO assembly factor, which is required for the expression of COX1 by assisting in the 
stability and translation of COX1 mRNA. 
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 Human SCO1 and SCO2 code for essential metallochaperones with ill-defined 
functions in the biogenesis of the CuA site of Cytochrome c Oxidase subunit II (COX2). 
Mutations in both SCO1 and SCO2 cause severe tissue-specific CcO assembly 
impairment accompanied by marked copper deficiency (100-102). However, both genes 
have been shown to be ubiquitously expressed, displaying a similar expression pattern 
across human tissues. In particular, another CcO deficiency characterized by 
hypertrophic cardiomyopathy with encephalopathy also with an early onset is due to 
mutations in the copper related assembly factor SCO2. Although the CcO deficiency 
was more severe in cardiac and skeletal muscle, autopsy analysis of the brain revealed 
spongiform neurodegeneration in midbrain, pons and medulla accompanied by gliosis 
and microglia proliferation in the thalamus, but lacked the typical LS lesions(103). 
Mutations in the other copper chaperone, SCO1 have been associated with completely 
different phenotypes. Valnot and collaborators (102) reported two neonate cases, the 
first one with severe metabolic acidosis and with hepatic failure consisting in 
microvesicular steatosis (lipid accumulation) and enlarged liver. The patient died at 2 
months of age. A severe CcO deficiency in liver and muscle (less than 1% of control 
values) was determined in postmortem tissues. The second case was a sibling born in 
early pregnancy that also presented with metabolic acidosis and neuronal involvement 
and died at 5 days of age. In both cases, the defect mapped to the SCO1 gene (102). A 
third case of SCO1 defect was just recently reported (104). This last patient presented 
with an early onset of hypertrophic cardiomyopathy accompanied by encephalopathy 
and hepatomegalia and died at 6 months of age. Ultrastructural analysis of the cardiac 
tissue showed accumulation of abnormal mitochondria of varying sizes, containing 
hemidense deposits. The liver had microvesicular steatosis and the muscle lacked 
ragged-red fibers (105). Defects in the heme-a biosynthetic pathway lead to different 
clinical presentation also with fatal outcome early on life (months to 2 years of age). 
The first COX10 mutation was found in a pediatric patient suffering fromataxia, muscle 
weakness, hypotonia and pyramidal syndrome, leukodystrophy and proximal 
tubolopathy accompanied by elevated lactate in both cerebrospinal fluid and blood 
(102). Other patients with mutations in COX10 presented anemia, sensorineural 
deafness and hypertrophic cardiomyopathy (106) and Leigh-like syndrome (107). The 
levels of CcO activity in COX10 patients ranged from 5 to 25% of control, depending 
on the tissues analyzed. Also few patients with defects of COX15 protein, which is 
involved in the synthesis of heme-a, the heme prosthetic group for CcO, have been 
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 documented. The patients present lactic acidosis, hypotonia and cardiomyopathy (106), 
nystagmus, motor regression, retinopathy and microcephaly (108).  
A report of two patients with an early onset of mitochondrial encephalopathy presenting 
asymmetrical brain atrophy, convulsions, hemiplegia and psychomotor developmental 
delay associated with low levels of Cytochrome c Oxidase activity in skeletal muscle 
showed that the defect mapped to the FASTKD2 (fas activated serine–threonine kinase 
domain 2) gene (109). Although the function of FASTKD2 is not known, this protein 
appears to be involved in apoptosis.  
The assembly factors described above along with mtDNA genes constitute candidate 
genes screened to diagnose the causes of CcO deficiency in patients. Recently, another 
yeast assembly gene with a human homolog that has been proposed as a screening 
candidate for CcO deficiencies is COX18, which is required for the insertion of COX2 
into the inner mitochondrial membrane. Unfortunately, mutational screening of COX18 
gene in a large cohort of patients with an unknown cause of CcO deficiency and where 
mutations in other candidate genes were already ruled out, failed to reveal any sequence 
abnormality for COX18 suggesting that mutations in this gene could be incompatible 
with life or not as frequent (110).  As mentioned earlier, not all the steps of CcO 
biogenesis and assembly factors discovered in yeast have been identified in humans. 
This is the case of factors related to mtDNA transcription and translation. A new human 
CcO assembly factor was identified studying a CcO deficient patient with Leigh 
syndrome with a slow progression of the disease. The CcO defect was due to a mutation 
in the CCDC44 gene that impaired COX1 protein synthesis. This gene encodes a 
protein, conserved in bacteria, that functions as a translational activator of COX1, and 
therefore was renamed TACO1 after its function (111). 
  
1.3.1 An overview on COX11 protein 
 
The most obvious candidate for delivery of copper to the mitochondrion was the 
COX17 protein. The latter exists in both the cytoplasm and mitochondrial inner 
membrane space (IMS)(112). Moreover it is known that yeast lacking COX17 
(COX17Δ yeast) is respiratory-deficient due to a complete lack of CcO activity (113). 
The simple prediction was that COX17 would shuttle Cu(I) into the IMS to be used in 
the assembly of CcO. This theory was strengthened by the observation that COX17 is a 
copper-binding protein (114). COX17 does not shuttle Cu(I) ions across the outer 
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 membrane (115). This implies that the primary function of COX17 is carried out within 
the IMS, where COX17 is metallated by using as a Cu(I) source the mitochondrial 
matrix copper pool (116). COX17 can also be metallated within the cytosol, where it 
mediates the Cu(I) metallation of a truncated SCO1 (117). However, this transfer 
reaction does not have any implications for a function of COX17 within the cytosol. 
The cytosolic protein might represent inefficient import or retention within the IMS. 
COX17 is postulated to transfer Cu(I) to SCO1 and COX11 proteins, indeed the latters 
appear to be co-metallochaperones assisting COX17 in the metalation of CcO (83).  
Human COX11 is a copper-binding protein of 276 amino acids ubiquitously expressed. 
It is a mitochondrial membrane polypeptide originally identified in yeast as essential for 
CcO activity and heme-a stability in subunit I (118). It has been shown that CcO 
isolated from Rhodobacter deficient in COX11 contains no CuB site, suggesting a role 
of this protein in formation of the binuclear copper–heme center (119). Consistent with 
this, biochemical studies indicate that COX11 is a copper-binding protein (120). While 
COX11 was found to be a dimmer, it remains possible that copper transfer to and from 
COX11 occurs through heterodimeric interaction of a single COX11 subunit with 
COX17 and COX1 respectively. It is unknown if COX11 mediated copper 
incorporation occurs after CcO assembly or co-translationally, prior to the association 
of COX1 with other subunits.  
COX11 protein presents a single transmembrane helix just downstream of the N-
terminal mitochondrial targeting sequence. Spectroscopic and mutagenesis studies 
indicate that copper ion in COX11 is ligated by two conserved cysteine residues. The C-
terminal domain of this protein forms a dimer that coordinates a single Cu ion per 
monomer. Mutation of these Cys residues reduces Cu(I) binding as well as CcO 
activity. Thus, the residues important for Cu(I)-binding correlate with in vivo function, 
suggesting that Cu(I)-binding is important in COX11 function (120). 
The structure of the globular domain of a COX11 homolog from Sinorhizobium meliloti 
adopts an immunoglobulin-like β fold (121)(Fig. 8).  
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Fig. 8: Solution structure of COX11. The COX11-homologue from Sinorhizobium 
meliloti adopts an immunoglobulin-like β fold with the conserved copperbinding 
cysteine residues on a flexible loop (shown by stick format) (121)  
 
COX11 dimerizes upon Cu(I) binding to form a binuclear Cu(I) thiolate cluster at the 
dimer interface (120). COX11 from Schizosaccharomyces pombe exists as a fusion 
protein with the partner protein being homologous to the S. cerevisiae protein Rsm22 
which is a component of the small subunit of mitochondrial ribosomes (122). Cells 
lacking Rsm22 are respiratory deficient. The presence of the Rsm22- like domain at the 
N-terminus of the S. pombe COX11 fusion protein suggests that COX11 may function 
to form the CuB site in nascent COX1 chains emerging from the mitochondrial 
ribosomes. Transfer of Cu(I) from COX11 to COX1 CuB site buried 13 Å below the 
membrane surface may occur in nascent COX1 chains extruded across the inner  
membrane  in a cotranslational process. COX11 weakly interacts with the mitochondrial 
ribosome, so heme-a3-CuB site formation likely occurs co-translationally (123). 
The above data mainly regards yeast and bacterium COX11 homologous, while detail 
are missed for human COX11. The function of human COX11 was predicted to be 
solely attributable to formation of CcO copper centers (81) and it is a possible candidate 
for human CcO deficiency.  
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 For this reason during my PhD I focussed my work to obtain the soluble C-terminal 
globular domain of COX11 in order to solve the solution structure by NMR and to 
better study how it binds Cu(I) and how it is involved in the assembly of CuB site of 
CcO.  
 
 
1.3.2 An overview on SURF1 protein 
 
SURF1 is an amphiphilic integral membrane protein of 300 amino acids ubiquitously 
expressed, but its expression is lower in brain than in other highly aerobic tissues (124). 
The SURF1 gene is located in a cluster of housekeeping genes known as the Surfeit 
locus (125) consists of at least six genes (SURF1-6), none of which is related by 
sequence homology.  It presents a characteristic mitochondrial signal peptide (MSP) at 
its N-terminus. Located in the inner mitochondrial membrane, SURF1 is predicted to 
form two transmembrane helices connected by a long region facing the intermembrane 
space (126, 127). Sequence alignments confirm the presence of SURF1 homologs in 
many eukaryotes and prokaryotes (94). One of the best studied SURF1 proteins is the 
yeast homolog SHY1p, which has been discovered and characterized in the context of 
pet mutants (126). Deletion of the gene leads to a strongly decreased CcO level, 
although the residual enzyme appears fully functional. This points to a role of SHY1p in 
assembly or stabilization of CcO, most likely during the formation of an early assembly 
intermediate consisting of the highly conserved core subunit I and II (128). So far, only 
three bacterial homologs have been inspected in closer detail. In Paracoccus 
denitrificans, two SURF1 homologs were identified and named SURF1c and SURF1q 
for their specific role in serving a heme-aa3-type CcO and a related heme-ba3-type 
quinol oxidase, respectively. With the function of SURF1 in CcO assembly still being 
speculative, a role in heme-a insertion into CcO subunit I seemed conceivable (129, 
130). SURF1 may modulate heme synthase activity by abstracting the product heme-a 
from the active site of CtaA (heme-a synthase in Paracoccus; COX15 in eukaryotes) 
and thus allows continuing heme synthesis. It avoids the presence and presumed 
detrimental action of free heme-a in the membrane by providing a safe, yet readily 
available pool of this cofactor, and specifically chaperones heme-a to its target sites in 
subunit I of CcO and positions the bulky cofactor for presumed co-translational 
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 insertion into both sites within the 12-transmembrane helix scaffold of CcO subunit I 
(131)(Fig. 9 ). 
 
 
Inter Membrane Space
Matrix
 
 
Fig. 9: Hypothetical role of SURF1 in co-translational incorporation of heme-a into 
CcO subunit I. Membrane-spanning SURF1 (yellow) in its unloaded apo form interacts 
with heme-a synthase (HAS, green) to receive the heme-a  group. SURF1 is suggested 
to interact directly with the nascent CcO subunit I polypeptide (orange) emerging from 
the ribosome (blue) eventually to receive both of its heme groups that are present in its 
fully folded form. Multiple copies of SURF1 depicted here denote its presumed heme-a 
pool function. (131) 
 
 
The importance of SURF1 in CcO biogenesis is exemplified by the fact that mutations 
in the human SURF1 gene, leading to a functional loss of the protein, are responsible for 
the Leigh syndrome associated with severe CcO deficiency and with loss of CcO 
activity. The precise role of SURF1 is, however still debated, but as SURF1 is a heme-a 
binding protein, it strongly indicates that SURF1 is involved in direct cofactor 
incorporation into CcO subunit I. The elucidation of the exact function of SURF1 may 
spur the development of a treatment for LS.  
During my PhD I tried to obtain the full length SURF1 protein in order to study the 
structure and to understand how it recives the heme-a from the heme-a synthase and 
how it release this group to the nascent CcO subunit I. This data should help to clarify 
how SURF1 protein is involved in CcO assembly and hence in the Leigh’s syndrome.   
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 1.4 Familial Amyotrophic Lateral Sclerosis 
 
A common motor neuron disease in human adults is Amyotrophic Lateral Sclerosis 
(ALS), also called Lou Gehrig's which is a fatal, late-onset, paralytic disorder first 
described in the late 1800s by the French neurologist Jean-Martin Charcot. The primary 
hallmark of ALS is the selective killing of motor neurons. Death usually occurs in 
within five years of symptom onset, typically from respiratory failure. In 90-95% of 
instances, there is no apparent genetic link and this form of disease is referred as a 
sporadic ALS, meaning that the afflicted individual has no family history. In the 
remaining 5-10% of cases, the disease is inherited in a dominant manner (a form 
referred to as familial ALS, FALS), meaning that a genetic lesion is passed from 
generation to generation (132, 133).  
The characteristic of ALS and FALS diseases is a progressive muscle weakness and 
athropy each of which reveals the degeneration and death of upper and lower motor 
neurons in the brain and spinal cord. Among FALS cases, approximately one in fifth 
have been directly attributed to autosomal dominant mutations in the gene (SOD1), that 
encodes the copper zinc superoxide dismutase (SOD1) protein (134),(135). Over one 
hundred mutations in SOD1 gene has been identified in FALS patients (136, 137) and 
the list is certain to grow longer as more patients will be analysed (a continually updated 
list can be found at the online database for SOD1/ALS genetic mutations 
www.alsa.org). Most of the individual mutations result in substitution of one single 
amino acid by another and they are scattered throughout the sequence of the protein 
(Fig. 10). None of the mutations eliminate the synthesis of a nearly full-length 
polipeptide (138). In addition to the these mutations there is also a smaller group of 
mutations resulting in amino acid deletions. An intriguing aspect of these mutations is 
that they occur throughout the gene and yet in most instances do not significantly lower 
the SOD activity of the resulting enzyme (139). 
Superoxide dismutases are the major antioxidant enzymes involved in free radical 
scavenging. These enzymes exist in three distinct forms, where two of them contain 
copper (SOD1 and SOD3), and the third one contains manganese (SOD2). Wild type 
(WT) human SOD1 is an exceptionally stable, homodimeric 32kDa protein, located 
mainly in the cytoplasm, but also present in the peroxisomes, in the mitochondrial 
intermembrane space and in the nucleus of eukaryotic cells (140, 141). 
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Fig. 10: ALS-causing mutations lie throughout the SOD1 polypeptide. Mutations in the 
153-amino-acid superoxide dismutase polypeptide that are known to cause amyotrophic 
lateral sclerosis (ALS)(138). 
 
 
 
Each subunit of the dimer binds one copper (binding residues: His46, His48, His63 and 
His120) and one zinc ion (binding residues: His63, His71, His80 and Asp83) and folds 
as an eight-stranded Greek-key β-barrel that is stabilized by an intra-subunit disulfide 
bond (Cys57, Cys146) near the active site (Figure 11)(142). In vivo, in the highly 
reducing cytoplasm environment, the existence of this intrasubunit disulfide bond points 
to its very low reduction potential. WT human SOD1 actually contains four cysteine 
residues per monomer. Besides the two cysteines involved in the formation of the 
intramolecular disulfide bond, two reduced cysteines Cys6 and Cys111 are located on β 
strand 1 and loop VI respectively. Among the loops connecting the eight β strands, two 
have structural and functional role. The electrostatic loop (loop VII, residues 121–144) 
contains charged residues that contribute to guide the negatively charged superoxide 
substrate towards the catalytic copper site. The long zinc loop (loop IV, residues 49–84) 
contains all the zinc binding residues including His63, which acts as a ligand to both 
metals (142). In mammals, SOD1 is ubiquitously expressed in all tissues and within 
cells it is primarily localized to the cytosol, although lesser amounts are found in the 
nucleus, peroxisomes, and mitochondria (141). SOD1 detoxifies reactive superoxide 
anion, a normal by-product of cellular respiration, to molecular oxygen and water (144), 
so the fundamental role of SOD1 is to act as an antioxidant protein. Loss of enzymatic 
function could lead to oxidative damage and death of neural cells.  
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Fig.11: SOD1 structure. Human Cu-Zn superoxide dismutase [pdb code 2C9V (29)]. 
The relationship of the two monomers is indicated. Intrasubunit disulfide bonds are 
shown as orange sticks, the metal-binding loops (loop IV and VII) are shown in blue 
and pink, respectively. Copper and zinc ions are shown as cyan and green spheres, 
respectively.(143) 
 
 
However, mice lacking SOD1 do not develop motor neuron disease (145) and 
transgenic mice expressing human FALS SOD1 mutants in addition to their own 
endogenous SOD1 develop paralytic symptoms strikingly similar to those observed in 
human patients(139,146,147). Together, these observations imply that pathogenic 
SOD1 molecules act through the gain of a cytotoxic property and not a loss of function. 
The insertion of copper into SOD1 requires a copper metallochaperone called CCS 
(copper chaperone for superoxide dismutase) (149,151). Yeast mutants lacking CCS 
express a form of SOD1 protein that is essentially apo for copper (151) but contains a 
single atom of zinc per subunit (149) (152). Mice with disruptions in CCS exhibit 
marked reductions in SOD1 activity, emphasizing the conserved requirement for CCS 
in activation of eukaryotic SOD1 (152). In brain SOD1 can not acquire its Cu in the 
absence of the CCS (153). Due to its biological function CCS is considered as a 
potential candidate gene for FALS. 
Human CCS is a three-domain polypeptide that confers at least two critical stabilizing 
posttranslational modifications on newly synthesized SOD1: the insertion of the 
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 catalytic copper ion (149), and the oxidation of the disulfide bond found within each 
SOD1 subunit (154). The presence of a disulfide bond is rare for cytosolic proteins 
given the strong reducing environment of the cytosol, and recent studies suggest that 
CCS-mediated oxidation of this disulfide bond occurs concomitant with copper delivery 
in an oxygen- or superoxide-dependent fashion (154). It is important to note that at the 
protein level, the ratio of SOD1 to CCS in the cytosol is estimated to be between 15:1 
and 30:1 (153), meaning that CCS must cycle through the newly translated SOD1 pool 
to activate these molecules (155). It is presumed that upon copper delivery to SOD1, 
CCS becomes recharged with copper via the membrane-bound copper transporter 
CTR1, although direct protein-protein interactions between CCS and CTR1 have not yet 
been demonstrated. 
Is suspected that pathogenic SOD1 mutations may result in increased levels of 
immature SOD1 folding intermediates by hindering the action of CCS at various points 
in the SOD1 maturation cycle. These immature SOD1 folding intermediates may lack 
some or all posttranslational modifications that are dependent upon CCS activity, 
including the insertion of copper co-factors and oxidation of the intrasubunit disulfide 
bond. Two recent in vitro studies indicate that failure to form the intrasubunit disulfide 
bond may be a key step (156, 157). Similarly, studies of aggregates isolated from cell 
culture and transgenic mouse models indicate that immature SOD1 molecules 
eventually end up in the insoluble inclusions (158). One possible explanation for these 
observations is that mutant forms of SOD1 interact with CCS in a manner that inhibits 
normal posttranslational modifications (for example, the nascent metal-binding 
mutants). Alternatively, some mutant forms may be so destabilized that CCS encounters 
only a fraction of these variants before they exit the soluble fraction or are turned over 
by the protein quality control machinery (for example, the nascent β-barrel mutants). 
 
1.4.1 An overview on CCS protein 
 
Human CCS is encoded by a single copy gene on chromosome 11, which is 
ubiquitously expressed in all human tissues. The protein is located in cytoplasm and  
binds copper ions and one zinc ion. CCS exists as a homodimer that may form a 
heterodimer with SOD1 during copper loading. Three functional domains have been 
described in the 274 amino acid long protein product (159, 160). 
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 CCS domain I (residues 1–85) contains a copperbinding motif MXCXXC that is 
postulated to acquire copper ion from the membrane copper transporter CTR1 (161). 
Domain II (residues 86–238) is similar to human SOD1 and retains amino acid residues 
found at the SOD1 dimer interface (162). Because dimer interface residues are 
conserved, domain II is proposed to be responsible for the specificity of CCS/SOD1 
interaction via the formation of a SOD1/CCS heterodimer (163). Domain III (residues 
239– 274) contains the copper-binding motif CXC, which is proposed to directly insert 
copper ion into nascent SOD1 (163). The ‘‘heterodimerization’’ model of CCS 
activation of SOD1 is shown in Fig. 12. It remains unclear what amino acid residues of 
both proteins participate in copper delivery and disulfide bond oxidation and, most 
importantly, how might FALS mutations in SOD1 interfere with CCS action, and what 
are the properties of the resulting immature SOD1 proteins.  
 
 
   
Fig. 12: Heterodimerization model of CCS action after O’Halloran and 
colleagues(161). Newly translated SOD1 monomers are shown in blue. CCS domain I is 
shown in red, CCS domain II is shown in green, and CCS domain III is shown in yellow 
(inset)(143). 
 
 
To probe various mechanistic aspects of CCS action, Blackburn and colleagues titrating 
purified human CCS with increasing concentrations of Cu(I) (164). Upon addition of a 
single equivalent of Cu(I) per CCS molecule, they observed that the ‘‘canonical’’ CCS 
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 dimer mediated by the SOD1-like domain II dissociated into monomers and that 
addition of additional equivalents resulted in the appearance of a ‘‘noncanonical’’ dimer 
mediated by a Cu4S6 copper cluster formed in part by the two CXC motifs of CCS 
domain III (Fig. 13).  
 
 
 
 
Fig. 13: Human CCS quaternary structure as a function of copper loading. The CCS 
canonical dimer [pdb code 1QUP (162)] reorganizes to form the noncanonical dimer 
[pdb code 1JK9(165)] upon the binding of Cu(I)(164), thereby freeing domain II to 
interact with nascent SOD1.(143) 
 
 
 
This canonical-to-noncanonical CCS dimer transition, if it occurs in vivo, would seem 
to act as a functional copper-sensing switch to make CCS domain II available to nascent 
SOD1 binding only when sufficient copper is available (164). Interestingly, a non-
canonical domain III mediated CCS dimer similar to that shown in Fig. 13 was also 
observed in the crystal structure of a yeast SOD1/yeast CCS complex, although no 
copper was present in the crystallization experiment (165). Taken together, these 
observations suggest an alternate model of CCS action shown in Fig. 14. The latter 
mechanism is particularly intriguing, given that CCS contains its own intrasubunit 
disulfide bond and bound zinc, which as described above, are both factors that are 
known to stabilize SOD1 dimers (166) and by extension, would be expected to stabilize 
CCS dimers. However, this new model has not been unambiguously validated and does 
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 not reveal precise mechanistic details of the posttranslational modification of SOD1 or 
how the binding of a single copper ion results in allosteric CCS dimer dissociation. For 
this reason one of my PhD projects was focussed to obtain the full length CCS protein 
in order to better understand the behaviour of the three domains in presence of Cu(I) by 
studying the solution structure and the interaction with this metal by NMR. Moreover it 
will be interesting to study the interaction of  CCS protein in presence of SOD. 
 
 
 
 
 
 
Fig. 14: An alternate model of CCS action and how the various pathogenic SOD1 
mutations may hinder CCS-mediated SOD1 maturation. (1) SOD1 is translated. (2) The 
canonical CCS dimer is loaded with Cu(I) to generate the noncanonical CCS dimer 
mediated by a Cu4S6 cluster (164). (3) Nascent SOD1 binds to domain II of CCS in the 
noncanonical, Cu(I)-loaded CCS dimer. (4) Zinc is loaded into SOD1 (this could also 
occur as early as step 1). (5–7) Cu(I) from the Cu4S6 cluster is transferred to nascent 
SOD1 and the intrasubunit disulfide bond in nascent SOD1 is oxidized(161). Upon 
being depleted with Cu(I), CCS reforms the canonical CCS dimer and the cycle repeats. 
The pathogenic SOD1 mutations listed in Table 1 may interfere with CCS-mediated 
SOD1 maturation at the various positions indicated.(143) 
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 2.1 Genome browsing 
One of the main challenges facing the molecular biology community today is to make 
sense of the wealth of data that has been produced by the genome sequencing projects. 
In the past decade, bioinformatics has become an integral part of research and 
development in the biomedical sciences. Bioinformatics now has an essential role both 
in deciphering genomic, transcriptomic and proteomic data, generated by high-
throughput experimental technologies, and in organizing information gathered from 
traditional biology. It is an interdisciplinary research area at the interface between the 
biological and computational science. The ultimate goal of bioinformatics is to uncover 
the biological information hidden in the mass of data and obtain a clearer insight into 
the fundamental biology of organisms.  
A number of data banks are available and provide the scientific community with tools 
for searching gene banks, for the analysis of protein sequences, for the prediction of a 
variety of protein properties.  
Primary databases contain information and annotations of DNA and protein sequences, 
DNA and protein structures and protein expression profiles. Some available databases 
for genome browsing are: 
• NCBI (http://www.ncbi.nlm.nih.gov/sites/entrez/pubmed) - This web site 
integrates information from several databases (Swissprot, EMBL, all geneBank, 
etc...) 
• PDB (http://www.rcsb.org/pdb/home/home.do) – A 3-D biological 
macromolecular structure database 
• Pfam (http://pfam.sanger.ac.uk/) - A collection of different protein families 
organized in terms of different domains as obtained from multiple alignment. 
Secondary or derived databases are so called because they contain the results of analysis 
of the primary resource including information on sequence patterns or motifs, variants 
and mutations and evolutionary relationships.  
Once all biological data are stored, the requirement is to provide bioinformatics tools 
for extracting the meaningful information. 
The most used programs for genome browsing are: 
• BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi): Standard BLAST (Basic Local 
Alignment Search Tool) is a set of similarity search programs designed to 
explore all of the available sequence databases regardless of whether the query is 
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 protein or DNA. PHIBLAST is designed to search for proteins that contain a 
pattern specified by the user, and simultaneously are similar to the query 
sequence. 
• CLUSTALW (http://www.ebi.ac.uk/Tools/clustalw2/index.html) is a general 
purpose multiple sequence alignment program for DNA or proteins. It produces 
biologically meaningful multiple sequence alignments of divergent sequences. It 
calculates the best match for the selected sequences, and lines them up so that 
the identities, similarities and differences can be seen. Evolutionary relationships 
can be seen via viewing Cladograms or Phylograms 
• PROSITE (http://www.expasy.ch/prosite/) SCANPROSITE allows to scan a 
protein sequence, provided by the user, for the occurrence of patterns and 
profiles stored in the PROSITE database, or to search in protein databases all 
sequences with a user entered pattern. 
• STRING (http://string.embl.de/) STRING is a database of predicted functional 
associations among genes/proteins. Genes of similar function tend to be 
maintained in close neighbourhood and tend to be present or absent together. 
 
In our research group the attention has been focused on three main themes: (i) studying 
target proteins involved in  rare diseases; (ii) finding new metal binding protein of 
unknown structure and function, with conserved consensus sequences for metal binding; 
(iii) discover in different organism metalloproteins homologues to the human ones. 
Once individuated a protein of particular interest, this is subjected to further 
bioinformatics investigations in order to predict important features like stability, 
solubility, hydrophobicity, secondary and tertiary structures. 
 
2.2 Domain definition 
 
Usually for each target protein several domains can be selected for expression, and of 
these domains various construct are cloned in order to increase the probability of 
obtaining a soluble and well-folded protein. Domain selection and construct design are 
performed considering several aspects. 
The first important step is to perform the transmembrane regions prediction using 
dedicated bioinformatics programs. (e.g.TMHMM: www.cbs.dtu.dk/services/TMHMM-
2.0) The result of this analysis make us know if we are dealing with a completely 
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 soluble protein, with an integral transmembrane protein or with a protein mainly soluble 
with a small portion inserted into the phospholipidic bilayer. In the latter case it is 
possible to try to express a recombinant protein without the transmembrane tail. Using 
the program SIGNALP (www.cbs.dtu.dk/services/SignalP) it is possible to predict the 
presence and location of a signal-peptide sequence that enables the expression of the 
protein in the periplasmic area. Similarly using the program MITOPROT 
(http://ihg2.helmholtz-muenchen.de/ihg/mitoprot.html)  it is possible to calculate the N-
terminal protein region that can support a mitochondrial targeting sequence and the 
cleavage site. 
Another important analysis to perform is the secondary structure prediction, e.g. 
exploiting the web server http://npsa-pbil.ibcp.fr/, in order to have an indication of the 
regions with tendency to form helices, beta-sheet, coil or turns. Combining these 
predictions with ClustalW alignments of the protein family, we can evaluate which are 
the domain borders, still maintaining the correct folding of the protein. It is also useful 
to search for the presence of intrinsically unstructured/disordered region using IUPred 
(http://iupred.enzim.hu/). 
 
2.3 Cloning strategy 
 
Proteins yield and solubility are highly dependent on the specific protein sequence, as 
well as on the vector, host cell, and culture conditions used. More is known about the 
characteristics of a protein, more easily it can be expressed, isolated and purified. For 
optimal efficiency, various combinations should be simultaneously screened, to 
determine the best conditions. The cloning strategy and the expression system are the 
first steps to be well designed since they will influence the expression protocol. The 
choice of the expression system depend on many factors, including cell growth 
characteristics, expression levels, intracellular and extracellular expression, 
posttranslational modifications, biological activity of the protein of interest (1, 2). For 
example, to express a protein of prokaryotic origin, the obvious choice is to use E. coli 
as host, but in case of eukaryotic proteins, different expression systems can be used and 
the choice will depend on many factors, since each system has its advantages and 
problems. Currently, many methodological improvement in non-prokaryotic hosts made 
more accessible and less expensive eukaryotic systems such as yeast, plants, 
filamentous fungi, insect or mammalian cells grown in culture and transgenic animals 
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 (3-5). Also cell-free protein syntesis has a great potential for the expression of 
problematic proteins (6). However, especially for characterizations that require high 
amount of labelled samples, such as NMR, the prokaryotic and in particular the E.coli 
expression system is the most widely used. The choice of the expression vector depends 
on the expression system. For E. coli, a lot of expression plasmids are available for the 
screening of different expression conditions that can influence the yield of soluble 
recombinant protein. Plasmid vectors possess an origin of replication (ori), a gene for 
antibiotic resistance (usually Ampicillin), which allows for selection of cell clones 
carrying the plasmid, and a multicloning site, for the insertion of the target protein 
coding sequence. Classical cloning, using restriction enzymes, typically cannot be 
adapted to high-throughput approaches, due to the complication of selecting compatible 
and appropriate restriction enzymes for each cloning procedure and to its multistep 
process. High-throughput cloning therefore requires procedures which can help the 
screening of a broad range of conditions in less time, for these reasons new cloning 
technologies have been developed in recent years (Fig. 1). 
                       
 
Fig. 1: Schematic comparison between the Classic and the Gateway cloning technology. 
Theoretically parallel cloning is possible in both the cases but the Gateway system 
resulted faster due to the higher reaction efficiency and less sequencing demand since 
only the starting pENTR should be sequence verified. 
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 Landy and co-workers have found a universal cloning method based on the site-specific 
recombination (7). Gateway system (Invitrogen) is based on the bacteriophage lambda 
site specific recombination system which facilitates the integration of  bacteriophage 
into the E. coli chromosome and the switch between the lytic and lysogenic pathways. 
Gateway system uses this machinery to clone a target gene into different expression 
vectors, without the time consuming reactions with restriction enzymes and ligase. PCR 
products made with primers containing terminal attB sites are substrates for the BP 
reaction. The result is an Entry Clone containing the PCR fragment(Fig.2). The entry 
vector can also be obtained via recombination reaction of the linearized pENTR/TOPO 
vector with our gene; the reaction is catalyzed by the topoisomerase I located on the 
pENTR vector. After isolation of the entry vector, the second step is to generate an 
expression construct by performing an LR recombination reaction between the entry 
clone and a Gateway destination vector of choice. 
 
 
 
 
 
Fig. 2: The Gateway cloning technology. PCR product can be transferred into an Entry 
Vector by the BP Reaction.Only plasmids without the ccdB gene that are also 
Kanamycin resistant (Kmr) will yield colonies. An Entry Clone, containing a gene 
flanked byrecombination sites, recombines with a Destination Vector by the LR 
Reaction to yield an Expression Clone and a by-product plasmid. The result is that a 
gene sequence in the Entry Clone is transferred into an Expression Vector with 
Ampicilline resistence (Apr), donated by the Destination Vector. The by-product 
plasmid contains the ccdB gene, and hence gives rise to no colonies when using 
standard strains of E. coli. 
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Important elements of an expression plasmid that affect recombinant protein yield and 
solubility, are the promoter and the fusion tag. Many promoter are available for protein 
expression in E. coli, but only a few of them are commonly used. A useful promoter 
must be strong, tightly regulated to have a low basal expression level, the induction 
must be simple and cost-effective, and should be independent on the commonly used 
ingredients of growth media. 
The most used promoter system for the bacterial expression of recombinant proteins is 
the T7/lac promoter (8). Genes under the control of T7/lac promoter can be transcribed 
by T7 RNA polymerase, in presence of lactose. Prokaryotic cells do not produce this 
type of RNA polymerase, and therefore only E. coli strains which has been genetically 
engineered to incorporate the gene for T7 RNA polymerase, the lac promoter and the 
lac operator in their genome, can be used for expression of  target proteins. When 
lactose or lactose derivative or analogue to lactose, such as Isopropyl β-D-1-
thiogalactopyranoside (IPTG), is added to the culture, it displaces the repressor from the 
lac operator. Since there are lac operators located upstream of the gene encoding the T7 
RNA polymerase in the bacterial genome and  of the gene encoding the target protein in 
the plasmid, IPTG activates both genes. The advantage of  IPTG respect to lactose is 
that it is not a substrate of β-galactosidase. Therefore, since it can not be metabolized by 
E. coli, its concentration remains constant and the rate of expression of lac promoter 
controlled genes is not a variable during the experiment. 
T7 RNA polymerase is so selective and active that, when fully induced, almost all of the 
cell’s resources are converted to target gene expression and the desired product can 
comprise up to 50% of the total cell protein in few hours after induction. If the 
expression of the recombinant protein has to be reduced, as in case of toxic or 
membrane proteins, host strains containing the pLysS or pLysE vectors can be used. 
These vectors express the T7 lysozyme, a natural inhibitor of T7 RNA polymerase. The 
target protein can be expressed with different fusion partners, which has been developed 
to increase the expression yield and the solubility of the recombinant proteins, even if 
sometimes the expression of the native protein could be the best choice(2). Fusion tags 
can also be exploited to facilitate the purification procedures. 
For example the ATP7B full leght (residues1- 633), ATP7B1-2 (residues 1-157) and the 
CCS1-2 (residues 1-238) entry vector are obtained via recombination reaction of the 
linearized pENTR/TOPO vector with the genes and then subcloned by LR reaction in 
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 pETG-20A (His6 tag) and pTH34 (GB1 tag) respectively. Instead SURF1 (reisdues 1- 
256), COX11 soluble part (reisdues 122-276) and CCS full length (reisdues 1-274) 
genes were cloned in pDONR 221 by BP reaction and then subcloned  in pTH27 
(COX11 and CCS full length) and pTH24 (SURF1) by LR reaction. 
 
2.4 Site-directed mutagenesis 
 
The functional analysis of a protein often requires the generation of a number of single 
or multiple amino acid variants of the wild type gene. Site-directed mutagenesis is a 
technique for carrying out vector modification and characterizing the dynamic, complex 
relationships between protein structure and function. The basic procedure utilizes a 
supercoiled double-stranded DNA vector with insert the gene of interest and two 
synthetic oligonucleotide primers, both containing the desired mutation. The primers, 
each complementary to opposite strands of the vector, are extended during PCR reaction 
by a high fidelity DNA polymerase (PfuUltra, Stratagene). Extension of the 
oligonucleotide primers generates a mutated plasmid. After PCR reaction the product is 
treated with an endonuclease specific for methylated and hemimethylated DNA, DpnI. 
This enzyme is used to digest the parental DNA template and thus select only the 
mutation-containing synthesized DNA; this happens because DNA isolated from almost 
all E. coli strains is dam methylated and therefore susceptible to endonuclease digestion. 
The vector containing the desired mutations is then transformed into XL1-Blue 
supercompetent cells and subsequently subjected to sequencing analysis. 
To obtain Cystein 1,2,4 mutant of ATP7B protein I designed primers with both 
Cysteines of the conserved motif CxxC  mutated in Alanines. The three mutagenesis 
reactions were performed one after the other, using as starting template the plasmid 
encoding for wild type ATP7B. 
 
2.5 Protein expression 
 
2.5.1 Expression systems 
 
At the moment, several host systems are available for protein expression, including 
bacteria, yeast, plants, fungi, insect and mammalian cells. The choice is strongly 
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 dependent upon the specific requirements for the final product, since it will affect not 
only the protein expression, but also the subsequent purification.  
Often the first choice is the E. coli system, since it is the easiest, quickest and cheapest 
one. There are many commercial and non-commercial expression vectors available with 
different N- and C-terminal tags and many different bacterial strains which are 
optimized for special applications. Moreover one of the major advantages of E. coli is 
that the production of isotope labelled protein for NMR is very easy in compare to other 
systems. However, E. coli is a prokaryote and lacks intracellular organelles, such as the 
endoplasmic reticulum and the Golgi apparatus that are present in eukaryotes, which are 
responsible for post-translation modifications of the proteins being produced. Many 
eukaryotic proteins can be produced in E. coli but sometimes they are produced like a 
non-functional inclusion bodies protein, since glycosylation or post-translational 
modifications such as proteolytic processing, folding and disulfide bond formation do 
not occur. Therefore, researchers have recently turned to eukaryotic yeast and insect cell 
expression systems for protein production. 
Yeast is a eukaryotic organism and has some advantages and disadvantages over E. coli. 
The major advantages are that yeast cultures can be grown to very high densities, which 
makes them especially useful for the production of isotope labelled protein for NMR, 
and the possibility to introduce some post-translational modification on the expressed 
protein (e.g. glycosylation). The main disadvantages are the higher prices of reagents 
required for isotope labelling and the very long time of growth (4-5 days instead of 1). 
The two most used yeast strains are Saccharomyces cerevisiae and the methanoltrophic 
yeast Pichia pastoris. 
Insect cells are a higher eukaryotic system than yeast and are able to carry out more 
complex post-translational modifications than the other two systems. They also have a 
better machinery for the folding of mammalian proteins and, therefore, give you the best 
chance of obtaining soluble protein when you want to express a protein of mammalian 
origin. The disadvantages of insect cells are the higher costs and the longer duration 
before you get protein (usually 2 weeks). 
All proteins studied in this project were expressed in E. coli cells. ATP7B was 
expressed in Rosetta (DE3) pLysS cells, while Surf1 and COX11 were expressed in 
C41(DE3) cells. CCS full length construct expression was detect in BL21(DE3) Codon 
Plus, while the short construct was expressed in Origami pLysS cells. 
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 2.5.2 Expression in E.coli 
 
In this section the methods used in our laboratory for protein expression optimization in 
E. coli are described. Other expression systems are not considered in detail since they 
have not been used in this thesis work.  
As like gene cloning, also for protein expression the best solution is the use of a parallel 
expression strategy; depending on the needed production throughput the two possible 
choices are: (i) to express more genes in the same bacterial strain or (ii) to express a 
single gene in different strains. In our lab the second approach is more often used.  
A preliminary expression test is performed in a small-volume scale using different 
strains, three expression temperatures (37-25-18°C), three inducer concentrations and 
different induction times (4h and 16h). Expression results are checked on Dot Blot in 
case of presence of an  His-tag and on SDS polyacrilamide gel (SDS-PAGE). This kind 
of approach allows us to explore a large set of expression conditions and to evaluate 
which one gives the best yield of soluble protein. A second expression test is sometimes 
performed to better refine the expression conditions before starting a massive culture 
that is performed in flasks or fermentors to increase protein yield and have a better 
parameter control (i.e. pH, temperature, pO2).  
In case of negative or partially positive results some or all variables can be modified, in 
particular the more influencing ones like the choice of bacterial strain(9) and the kind of 
vectors. The majority of the target proteins are produced in the soluble fraction, but in 
case it is detected in the insoluble fraction, a possible approach is to try an in-vitro 
refolding screening with different additives in order to get a folded and soluble protein. 
The last choices are to redesign the expressed domains or to switch to other expression 
system.  
Obviously when dealing with small bacterial proteins this procedure may be simplified, 
since the targets do not require a lot of efforts to be expressed in a soluble form, 
whereas bigger human proteins create more problems.  
In dependence of the spectroscopic technique of choice, protein expression is performed 
in differently composed media. In fact, when large amounts of proteins must be isolated 
for techniques that do not require isotopic labelling, the culture is usually performed in a 
so-called rich or complex medium. Complex media contain water soluble extracts of 
plant or animal tissue (e.g., enzymatically digested animal proteins such as peptone and 
tryptone), and for this reason are rich in nutrients and minerals, assuring a fast bacterial 
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 growth and a high expression level. Their exact composition is unknown and this can 
impair the reproducibility of cultures. Chemically defined (or minimal) media are 
composed of pure ingredients in measured concentrations, dissolved in milliQ water; 
this way the exact chemical composition of the medium is known, allowing high 
reproducibility of protein yields and grade and type of interferents. Typically, this class 
of media is composed of a buffering agent to maintain culture pH around physiological 
values, a carbon and energy source like a simple sugar (glucose) or glycerol, and an 
inorganic nitrogen source, usually an ammonium inorganic salt. In dependence of the 
bacterial strain and of the expressed proteins various mineral salts can be added and, if 
necessary, growth factors such as purified amino acids, vitamins, purines and 
pyrimidines. Chemically defined media are easier to isotopically enrich, simply using 
15N and 13C enriched nitrogen and carbon sources in its composition, even if 
isotopically enriched complex media are also commercially available.  
Uniform labelling of proteins is particularly important when dealing with 2D and 3D 
NMR. 15N is very convenient because of the strategic locations of nitrogens in the 
backbone, and the absence of homonuclear couplings due to the intervening carbons. 
The replacement of all the carbons with 13C is also possible, although in this case the 
spectroscopy has to deal with the network of couplings among bonded carbons. Partial 
or total deuteration (perdeuteration) attenuates the dipolar couplings among protons, 
reducing the relaxation rates of NMR-active nuclei, since the gyromagnetic ratio of 2H 
is 6.5 times smaller than 1H. This last kind of enrichment is the most difficult to achieve 
since incorporation of 2H reduces the growth rate of organisms up to 50%, and 
decreases protein production as a consequence of the isotopic effect. For this reason, 
deuteration requires a gradual adaptation of bacteria to increasing concentration of D2O. 
 
2.6 Protein purification 
 
The strategy of purification depends mainly upon the location of the expressed protein 
within the host; for example the protein can be secreted into the growth media, 
transported in the periplasmic space, located in the membrane or expressed like a 
soluble or insoluble (inclusion bodies) protein within the cytoplasm. In each of the cases 
the isolation has to be performed in different ways. 
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 The majority of the proteins are usually expressed as soluble, while in few cases are 
expressed as insoluble proteins. Indeed, the most of the bacterial proteins are removed 
by different extraction steps with native buffer conditions, while the recombinant 
proteins are extracted from inclusion bodies with a denaturing buffer. Physical-chemical 
properties of the recombinant protein also drive the choice of purification protocols, 
thanks to peculiar properties of the recombinant protein.  
Cell lysis is the first step in protein purification and the technique chosen for the 
disruption of cells must be compatible with the amount of material to be processed and 
the intended downstream applications. Many techniques are available, spanning from 
physical to detergent-based methods. Among the first class are mechanical disruption, 
liquid-based homogenization, such as the French press, where cells are lysed by forcing 
the suspension through a narrow space, and sonication, which uses pulsed, high 
frequency sound waves to agitate and lyse cells. Gentler ways of disrupting cells are 
freeze-thaw lysis, detergent lysis, enzymatic lysis and osmotic lysis.  
The following step of purification procedure is composed of normally two or more 
rounds of chromatography, playing on the different physical chemical and biological 
characteristics of the protein.  
In case of peptide fusion tags, a variety of affinity purification methods are available. 
The basic principle is that the protein tag specifically interacts with an affinity resin and 
binds the tagged protein whereas other polypeptides are not bound. This allows a simple 
purification by releasing the tagged protein with a suitable competing buffer. In this 
case, usually an intermediate purification step includes the cleavage of the fusion tag 
with proteases such as Enterokinase, Factor Xa, Thrombin or Tobacco Etch Virus 
(TEV) in dependence of the cleavage site. The protease recognition site is selected and 
cloned in the vector codifying for the protein sequence at the cloning step; pilot 
experiments should be done to find out suitable cleavage conditions. The fusion protein 
is then separated, either with a second round of affinity purification, or by size 
exclusion chromatography provided that the difference in size with the target 
polypeptide is large enough. There are a lot of different affinity tags and some of them, 
like Maltose Binding Protein (MBP) or Glutathione-S-transferase (GST), have also the 
role of facilitating soluble expression(10). Currently Immobilized Metal Ion Affinity 
Chromatography (IMAC) is the most used affinity technique; it exploits the interaction 
between chelated transition metal ions (generally Zn2+ or Ni2+) and side-chains of 
specific amino acids (mainly histidine) added on the protein. In IMAC chromatography, 
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 the target protein is usually washed from the impurities and eluted using increasing 
concentration of imidazole, which acts like a competitive agent. Histidine-tagged (His6 
tag) proteins can also be eluted from the column lowering the pH to decrease the 
binding affinity or stripping the metal ions from the column with EDTA. His6 tag is 
removed as described. The procedure is illustrated in Fig. 3. 
 
 
Fig. 3: General purfication procedure for His-tag proteins.  
 
 
Gel filtration is the simplest and mildest of all the chromatographic techniques; the 
support for gel filtration chromatography is composed of beads which contain holes, 
called "pores," of given sizes. Larger molecules, which can't penetrate the pores, move 
around the beads and migrate through the spaces which separate the beads faster than 
the smaller molecules, which may penetrate the pores; in this technique the buffer 
composition does not play any role in the resolution. Size exclusion can be performed 
on a “rough” level, separating the components of a sample in major groups to remove 
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 for example high or low molecular weight contaminants or to exchange buffers, while 
high resolution fractionation of biomolecules allows to isolate one or more components 
of a protein mixture, to separate monomers from aggregates and last but not least to 
determine molecular weights or to perform a molecular weight distribution analysis, 
provided that suitable standards are available. 
For ATP7B, SURF1 and CCS proteins, all of them fused with His6 tag, HisTrap 
chelating column was used for purification, while for COX11 protein gel filtration was 
performed after refolding. 
 
 
2.6.1 Membrane protein purification 
 
A particular protocol must be used for membrane proteins. In contrast to soluble 
proteins, the isolation of a peripheral or integral membrane protein requires extraction 
of the biological membrane containing the protein of interest prior to purification. 
Extraction of integral membrane proteins is commonly accomplished by solubilizing the 
protein-containing membrane fraction using a variety of detergents which are necessary 
to disrupts the lipid bilayer and brings the proteins into solution as protein-lipid-
detergent complexes. (Fig.4).         
  
                              
 
Fig. 4: Solubilization of membrane protein by detergent with formation of  a water-
soluble protein-lipid-detergent complex.  
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 Detergents are amphiphilic molecules that mimic the lipid environment, which 
surrounds the protein in the membrane and keep the protein  soluble in acqueous 
buffers. These molecules are composed of  an hydrophilic head and an hydrophobic tail.  
There are several different types of detergents and are divided into groups according to 
the chemical property of the head part: ionic, non-ionic or zwitterionic. The head part of 
the ionic detergents can be either positive or negative, while zwitterionic detergents 
have both a positively and a negatively charged head group. One of the most harsh 
detergent is Fos-choline 12 (FC12) which is usually used to verify if a membrane 
protein is able to be solubized. For this reason FC12 was used to solubilised SURF1 
protein from the membrane. 
Following initial solubilization in high concentrations of detergent, intrinsic proteins 
can then be purified to homogeneity using a variety of biochemical techniques in the 
presence of relatively low concentrations of detergent. Solubilized membrane proteins 
from diverse sources and with different properties have successfully been purified by a 
combination of standard techniques such as gel filtration and different forms of the 
affinity chromatography method.  
 
2.6.2 Refolding 
 
Inclusion body formation is often an undesired event and a number of approaches can 
be utilized to obtain soluble protein. On the other hand, inclusion body formation does 
not necessarily have to be a dead-end process. Sometimes harvesting of proteins from 
inclusion bodies can prove to be very fruitful and may present a valid option for 
successful purification. New strains of E.coli and fusion partners are available, which 
offer a range of options to minimize, or maximize, inclusion body formation. Inclusion 
bodies are dense amorphous aggregates of misfolded protein. They are generally formed 
if a protein has a high propensity to misfold and aggregate, or if the cellular protein 
production machinery is unable to operate efficiently. The formation of inclusion bodies 
can sometimes be especially advantageous  if the protein is toxic to the cell or 
susceptible to proteolytic attack. Successful renaturation depends on the purity of 
inclusion bodies, as contaminants can decrease the efficiency of renaturation, 
presumably as such contaminants can promote coaggregation. Inclusion bodies are 
therefore best washed and centrifuged a several times in buffer containing detergents 
such as Triton X-100. Following washing, inclusion bodies are then solubilized, usually 
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 with GdnHCl or urea. It is important that during unfolding any disulfide bonds present 
are also reduced – this is usually achieved with β- mercaptoethanol or DTT. Upon 
solubilization of inclusion bodies, ample incubation time should be allowed for 
complete unfolding to occur. The renaturation process aims to effectively remove the 
denaturant and thiol reagents and allow the protein to refold. The refolding process is a 
competing reaction with misfolding and aggregation events and its success depends on a 
number of factors. Several different methods can be used to refold proteins. These 
include dialysis, dilution and column chromatography techniques. The method selected 
depends on the propensity of the protein to aggregate and the kinetics of refolding. 
Refolding by dilution can be described as ‘rapid’ or ‘slow’. In rapid dilution, the 
denatured protein is delivered to the refolding buffer such that in a very short time 
period, the concentrations of both the protein and denaturant decrease rapidly. The aim 
of dilution is to remove the denaturant, so its final concentration should be low. Rapid 
dilution has been used successfully for a range of proteins, however, the time period 
used dilution may be detrimental for some proteins, especially if they usually refold 
over a relatively long time period of minutes to hours. Forcing the protein to adopt its 
conformation in a short time frame may increase its chances of misfolding and 
aggregation. Slow dilution is an alternative method, as it is a more gentle approach and 
dramatically decreases the effective concentration of the refolding protein. 
In refolding by dialysis, which is the protocol that was used to refold COX11 protein in 
my PhD project, the concentrated denatured protein is dialyzed against a refolding 
buffer, such that the concentration of denaturant decreases with buffer exchange. This 
slow removal of denaturant allows refolding to occur. Unfortunately, the slow removal 
of denaturant often results in the formation and exposure of long lived intermediate 
species over a time period and hence there may be an increased propensity for the 
protein to aggregate. A variation of one-step dialysis, where protein is dialyzed against 
refolding buffer containing no denaturant, is the use of a series of refolding buffers with 
decreasing denaturant concentrations. 
On-column refolding has been applied to several proteins with success and offers an 
alternative where other methods may not be fruitful. If a protein has a His6 tag, it can be 
immobilized on a Ni2+ affinity column in its denatured state. By applying buffers with 
a decreasing concentration of denaturant, either step-wise or by using a gradient, the 
protein can be refolded and then eluted(11). 
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 2.7 Protein characterization 
 
2.7.1 Mass Spectrometry 
 
Mass spectrometry is an analytical tool used for measuring the molecular mass of a 
sample. For large samples such as biomolecules, molecular masses can be measured to 
within an accuracy of 0.01% of the total molecular mass of the sample. Mass 
Spectrometry can be used for different types of characterization: 
− Accurate molecular weight measurements, to determine the purity of a sample, to 
verify amino acid substitutions, to detect post-translational modifications, to calculate 
the number of disulphide bridges; 
− Reaction monitoring: monitor enzyme reactions, chemical modification, protein 
digestion; 
− Amino acid sequencing: sequence confirmation, characterisation of peptides, 
identification of proteins by database from proteolytic fragmentation; 
− Protein structure: protein folding monitored by H/D exchange, protein-ligand complex 
formation under physiological conditions, macromolecular structure determination. 
Mass spectrometers can be divided into three fundamental parts: the ionisation source , 
the analyser and the detector. Sample molecules are ionised in the ionisation source, 
these ions are extracted into the analyser region of the mass spectrometer where they are 
separated according to their mass (m) -to-charge (z) ratios (m/z) . The separated ions are 
detected and this signal sent to a data system where the m/z ratios are stored together 
with their relative abundance for presentation in the format of a m/z spectrum. 
Many ionisation methods are available, each with its own advantages and 
disadvantages, and the choice depend on the type of sample under investigation and the 
mass spectrometer available. The ionisation methods used for the majority of 
biochemical analyses are Electrospray Ionisation (ESI) and Matrix Assisted Laser 
Desorption Ionisation (MALDI). The main function of the mass analyser is to separate, 
or resolve, the ions formed in the ionisation source of the mass spectrometer according 
to their mass-to-charge (m/z) ratios. There are a number of mass analysers currently 
available, the better known of which include quadrupoles, time-of-flight (TOF) 
analysers, magnetic sectors, and both Fourier transform and quadrupole ion traps.  
These mass analysers have different features, including the m/z range that can be 
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 covered, the mass accuracy, and the achievable resolution. The detector monitors the 
ion current, amplifies it and the signal is then transmitted to the data system where it is 
recorded as mass spectra, where the m/z values of the ions are plotted against their 
intensities to show the number of components in the sample, the molecular mass of each 
component, and the relative abundance of the various components in the sample. 
MALDI is widely used in biochemical areas for the analysis of proteins, peptides, 
glycoproteins, oligosaccharides, and oligonucleotides and usually is performed in 
denaturing conditions. MALDI is based on the bombardment of sample molecules with 
a laser light to bring about sample ionisation. The sample is pre-mixed with a highly 
absorbing matrix compound which transforms the laser energy into excitation energy 
for the sample, which leads to sputtering of analyte and matrix ions from the surface of 
the mixture. The time-of-flight (TOF) analyser separates ions according to their 
mass(m)-to-charge(z) (m/z) ratios, by measuring the time it takes for ions to travel 
through a field free region known as the flight tube. The heavier ions are slower than the 
lighter ones. In negative ionisation mode, the deprotonated molecular ions (M-H-) are 
usually the most abundant species, accompanied by some salt adducts and possibly 
traces of dimeric or doubly charged materials. Negative ionisation can be used for the 
analysis of oligonucleotides and oligosaccharides. In positive ionisation mode, the 
protonated molecular ions (M+H+) are usually the dominant species, although they can 
be accompanied by salt adducts, a trace of the doubly charged molecular ion at 
approximately half the m/z value, and/or a trace of a dimeric species at approximately 
twice the m/z value. Positive ionisation is used in general for protein and peptide 
analyses. 
 
 
2.7.2 Circular Dichroism 
 
Circular Dichroism (CD) is an excellent method to analyze protein and nucleic acid 
secondary structure in solution and it can be used to follow the changes in folding as a 
function of temperature or denaturant. CD is a phenomenon occurring when 
asymmetrical molecules interact with circularly polarized light, thus absorbing left and 
right hand circularly polarized light with different absorption coefficients. In proteins 
the major optically active groups are the amide bonds of the peptide backbone, typically 
disposed in highly ordered arrays such as α-helices or β-pleated sheets. In dependence 
of the orientation of the peptide bonds in the arrays, given by the symmetry of its 
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 disposition, optical transitions are differently split by exciton splitting, thus yielding 
characteristic spectral profiles for each of the three basic secondary structures of a 
polypeptide chain. A protein consisting of these elements will therefore display a 
spectrum that can be deconvoluted into the tree individual contributions; for this 
purpose several mathematical methods have been developed, all of them relying on the 
assumption that the spectrum of a protein can be represented by a linear combination of 
the spectra of its secondary structural elements, plus a noise term which includes the 
contribution of aromatic chromophores.  
Circular dichroism spectroscopy is particularly good to: 
· determine whether a protein is folded, and characterize its secondary structure content. 
· compare the secondary structure elements content of proteins obtained from different 
sources (e.g. species or expression systems) or comparing structures for different 
mutants of the same protein.  
· study the conformational stability of a protein upon the change of various condition 
(thermal stability, pH stability, and stability to denaturants) and how this stability is 
altered by buffer composition or addition of stabilizers. 
· determine whether protein-protein interactions alter the conformation of protein. 
 
 
2.7.3 Light Scattering 
 
 
Static and dynamic light scattering represent an approach to studying protein complexes 
and oligomerization. In static light scattering, the scattering intensity is related to the 
molecular weight of the protein, in addition to its concentration, the scattering angle, 
and the wavelength. Dynamic light scattering is based on the auto-correlation of the 
time dependent fluctuations of scattered light intensity, which in turn depends upon the 
diffusion constant. This auto-correlation decays more slowly for slowly diffusing 
particles and thus, the diffusion constant is extracted from the value of the relaxation 
time of this function. In the case of ideal spherical particles, this provides a measure of 
the molecular weight. Light scattering is limited principally by sensitivity, with best 
results around 1 mg/ml, depending upon the size of the protein or the complex. While 
sensitivity limits preclude the determination of affinities and association or dissociation 
rate constants in most cases, light scattering is quite useful in characterizing the 
stoichiometry of complexes at high concentration.  
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 2.8 Structural characterization 
 
In order to understand completely the function of a protein the determination of the 3D 
structure is of basic importance. X-ray crystallography and NMR spectroscopy are the 
two main techniques that can provide structures of macromolecules at atomic 
resolution. Both techniques are well established and play a key role in structural biology 
as a basis for a detailed understanding of molecular functions. Their respective different 
advantages and disadvantages in terms of sample preparation and data collection and 
analysis make these two approaches complementary in Structural biology.  Most (75%) 
of the NMR structures in the Protein Data Bank (PDB) do not have corresponding 
crystal structures, and many of these simply do not provide diffraction quality crystals. 
On the other hand structure determination of big proteins (more than 50 kDa) or of 
membrane protein is affordable only by X-ray spectroscopy. 
 
2.8.1 Structural determination by NMR spectroscopy 
 
Nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography can 
provide high-resolution structures of biological molecules such as proteins and nucleic 
acids and their complexes at atomic resolution. NMR can study molecules in solution, 
therefore, crystallization is not required, and crystal packing affects may not influence 
the structure, especially on the surface of a protein. Solution studies should be closer to 
native-like conditions found in the cell. Since crystals are not needed, protein folding 
studies can be monitored by NMR spectroscopy upon folding or denaturing of a protein 
in real time. More importantly, denatured states of a biomolecule, folding intermediates 
and even transition states can be characterized using NMR methods. NMR provides 
information about conformational or chemical exchanges, internal mobility and 
dynamics at timescales ranging from picoseconds to seconds, and is very efficient in 
determining ligand binding, and mapping interaction surfaces of protein/protein, 
protein/nucleic acid, protein/ligand or nucleic acid/ligand complexes and intramolecular 
interactions. Improvements in NMR hardware (magnetic field strength, cryoprobes) and 
NMR methodology, combined with the availability of molecular biology and 
biochemical methods for preparation and isotope labeling of recombinant proteins, have 
dramatically increased the use of NMR for the characterization of structure and 
dynamics of biological molecules in solution. Protein isotope labelling is necessary for 
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 NMR analysis because not all atoms are magnetically active. The nuclei of naturally 
occurring atomic isotopes that constitute biological molecules have a nuclear spin 
determined by the spin quantum number (I) and its value depends on the composition of 
neutrons and protons in each nucleus. Because of the positive charge possessed, the 
nucleus rotation around its own axis generate a magnetic moment (m). Only atoms with 
I≠0 can be observed by NMR spectroscopy. For example, 12C is the most abundant 
isotopes in nature, but it has I=0, for this reason labelling with 13C is performed for 
biomolecules studied by NMR spectroscopy. Nuclei which have a spin of one-half, like 
1H, or 13C, have two possible spin states: m = ½ or m = -½ (also referred to as α and β, 
respectively). The energies of these states are degenerated, hence the populations of the 
two states will be approximately equal at equilibrium. If a nucleus is placed in a 
magnetic field, there is interaction between the nuclear magnetic moment and the 
external magnetic field, then the nuclear spin state aligned with the external magnetic 
field will be more populated and the different states will have different energies. When 
a radiofrequency pulse is applied to match this energy difference, resonance absorption 
will occur and all nuclei of the same element would resonate at the same frequency. The 
resonance frequency is affected by the chemical environment of each nucleus, hence 
nuclei of the same element will have differences in the resonance frequency due to the 
interference of surrounding electrons, that decrease the magnitude of the effective 
magnetic field on the nucleus. These differences are called chemical shifts and are 
higher for more shielded nuclei. The chemical shift value depends also on the applied 
magnetic field and in order to have chemical shift values normalised on the static 
magnetic field strength, they are measured in parts per million (ppm). 
In a protein, the resonance frequencies of each nucleus vary slightly due to chemical 
shifts, then a very short radiofrequency pulse is applied which inherently encodes a 
range of frequencies allowing to induce resonance for the whole frequency spectrum in 
one experiment (Fourier transform, FT NMR). Transient signals are detected as the 
system returns to equilibrium. The response obtained from a FT NMR experiment is a 
superposition of the frequencies of all spins in the molecule as a function of time. In 
order to obtain the corresponding spectrum as a function of frequency, a Fourier 
transformation is performed. Fourier transformation is a mathematical operation which 
translates a function in the time domain into the frequency domain. In large molecules, 
such as proteins, the number of resonances can be several thousand and a one-
dimensional spectrum inevitably has overlaps. For this reason, proteins NMR spectra 
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 cannot be resolved in a conventional one-dimensional spectra (1D) and multi-
dimensional nuclear magnetic resonance spectroscopy is required to correlate the 
frequencies of different nuclei. There are different types of experiments that can detect 
through-bonds and through-space nucleusnucleus interactions. 
The Heteronuclear Single Quantum Correlation (HSQC) spectrum is a 2D spectrum, 
where "heteronuclear" refers to nuclei other than 1H. In theory the heteronuclear single 
quantum correlation has one peak for each H bound to a heteronucleus. Thus the 1H 
15N-HSQC spectrum contains the signals of the HN protons in the protein backbone. 
Since there is only one backbone HN per amino acid, each HSQC signal represents one 
single amino acid, with the exception of proline, which has no amide-hydrogen due to 
the cyclic nature of its backbone. Moreover, this HSQC also contains signals from the 
NH2 groups of the side chains of Asn and Gln and of the aromatic HN protons of Trp 
and His. The acquisition of NMR signals is performed during the relaxation process, 
which restore the equilibrium of the system. There are two types of relaxation: 
− transverse relaxation, due to the interaction between different spins, and measured by 
the T2 time, which is directly proportional to the molecular weight; 
− longitudinal relaxation, due to the interaction between spins and solvent molecules, 
and is measured by the T1 time. 
The main problem in studies of biomolecules with molecular weights above 30 kDa is 
the fast decay of the NMR signal due to relaxation. Indeed, the line widths in the NMR 
spectra are inverse proportional to the relaxation rates. Therefore the signal-to-noise in 
NMR spectra of larger molecules is poor, due to poor resolution and sensitivity. There 
are NMR methods that can help the acquisition of spectra of large biomolecules, one of 
them is Transverse Relaxation Optimized Spectroscopy (TROSY). With these 
improvements high-resolution TROSY-HSQC spectra can be recorded of 
macromolecules with molecular weights up to several 100 000 Daltons. The exchange 
between two conformations, e.g. free and ligand bound forms of a protein, but also 
chemical exchange usually gives rise to two distinct NMR signals for a given spin due 
to different chemical environments in the two exchanging forms. If the exchange rate is 
slow on the chemical shift time scale, two sets of signals are observed, if the exchange 
rate is fast on the chemical shift time scale only one signal is observed at an average 
frequency corresponding to the populations of the two conformations. Intermediate 
exchange gives rise to very large line width. 
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 Molecular interactions can be very efficiently characterized using very sensitive NMR 
experiments. Changes in the environment of a spin due to binding of a ligand give rise 
to chemical shift changes in the NMR spectrum. These changes are usually largest near 
the binding site. Therefore, the binding surface of a protein with a ligand can be 
mapped. In addition, from NMR titration experiments dissociation constants can be 
determined. Due to the relatively high sample concentration, even very weak 
interactions can be detected. Additional structural information, and long range 
interactions, as the relative orientation of two protein domains can be measured by the 
observation of Residual Dipolar Couplings (RDCs). Dipolar coupled spins are the result 
of spin/spin interactions through space and depend on the distance between the two 
spins and the orientation of the internuclear vector with respect to the static magnetic 
field. The chemical shift difference between 1H-15N (1H-15N J-coupling constant), is 
different in isotropic or anisotropic conditions.  
 
 
2.8.2 X-ray and protein crystallization 
 
X-ray crystallography is another technique used to characterize proteins and is 
essentially a form of very high resolution microscopy. It enables to visualize protein 
structures at the atomic level and enhances our understanding of protein function. With 
this technique it is possible to study how proteins interact with other molecules, how 
they undergo conformational changes, and how they perform catalysis in the case of 
enzymes. In all forms of microscopy, the amount of detail or the resolution is limited by 
the wavelength of the electro-magnetic radiation used. In order to see proteins in atomic 
detail we need to work with electro-magnetic radiation with a wavelength of around 0.1 
nm or 1 Å. 
The diffraction from a single molecule would be too weak to be measurable. So it is 
necessary to use an ordered three-dimensional array of molecules, in other words a 
crystal, to magnify the signal. Even a small protein crystal might contain a billion 
molecules. If the crystal is well ordered, then diffraction will be measurable at high 
angles or high resolution and a detailed structure should result. The X-rays are 
diffracted by the electrons in the structure and consequently the result of an X-ray 
experiment is a 3-dimensional map showing the distribution of electrons in the 
structure.  
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 In order to crystallize a protein, the purified protein undergoes slow precipitation from 
an aqueous solution. As result, individual protein molecules align themselves in a 
repeating series of "unit cells" by adopting a consistent orientation. The production of 
good crystals is dependent upon a number of environmental factors, especially protein 
purity and pH conditions are very important. 
In the past few years macromolecular crystallography has become a standard technique 
used by many pharmaceutical and biotechnology companies. This methodology offers 
details of protein-ligand interactions at levels of resolution virtually unmatched by any 
other technique, and this approach holds the promise of novel, more effective, safer and 
cheaper drugs. Although crystallography remains a laborious and rather expensive 
technique, remarkable advances in structure determination and structure based drug 
design (SBDD) have been made in recent years. 
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 4.1 Introduction 
 
 
Cytochrome c Oxidase (CcO) is the terminal electron acceptor of the mitochondrial 
respiratory chain. In mammals, this protein consists of 13 individual subunits, 3 of 
which, subunits I–III (COX1, COX2, COX3), are encoded in the mitochondrial genome 
and serve as the catalytic centers binding copper and heme. In particular CcO has two 
copper binding sites (CuA and CuB), two hemes (a and a3), a magnesium and a zinc 
ion. The binuclear CuA site is located in COX2 and the CuB site is located in COX1 
togheter with the two hemes. Electrons flow from reduced cytochrome c to the binuclear 
CuA site, then to heme-a before entering the oxygen binding heme-a3-CuB site (1).  
Biogenesis of mitochondrial CcO relies on a large number of assembly factors. SURF1 
and COX11 proteins are both involved in this process and associated to CcO deficiency.  
The loss of human SURF1 membrane protein function is associated with Leigh 
syndrome, an autosomal recessive inherited neurodegenerative disorder characterized 
by focal, bilateral lesions in one or more areas of the central nervous system.  
Human SURF1 is the first gene of the SURFEIT gene locus on chromosome 9, encodes 
a 30-kDa protein (2, 3). Located in the inner mitochondrial membrane, SURF1 is an 
amphiphilic integral membrane protein ubiquitously expressed. It presents a 
mitochondrial signal peptide (MSP) at N-terminus and it is predicted to form two 
transmembrane helices connected by a long loop facing the intermembrane space (4), 
(5). Sequence alignment confirm the presence of SURF1 homologs in many eukaryotes 
and prokaryotes (6).  Even if  is known that mutations in the SURF1 gene leads to Leigh 
syndrome, the role of the protein in this disease remains unclear. It was suggested that 
the apo SURF1 protein  interacts with heme-a synthase to receive the heme-a group and 
then probably interacts directly with the nascent CcO subunit I polypeptide emerging 
from the ribosome (7).  
During my PhD I try to obtain the whole 256aa SURF1 protein segment without the 
MSP(Fig.1) in order to characterize and solve the structure by NMR and to study its 
role in the CcO assembly. 
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Fig.1: A scheme of SURF1 protein. In my study I removed the MSP in order to obtain 
only  the segments with the two transmembrane domains. 
 
 
 
COX11 is a copper-binding protein originally identified in yeast as essential for CcO 
activity and heme-a stability in COX1 (8). Actually we know that it is implicated in the 
assembly of the two copper centers of CcO, indeed it presents two conserved Cys 
residues which are candidate ligands for the Cu(I) ion. For this reason it is hypothesized 
that it is involved in CcO deficiency (9). 
COX11 is a 28KDa protein ubiquitously expressed and it is located in the inner 
mitochondrial membrane. It is anchored to the membrane by a single transmembrane 
segment and presents a soluble C-terminal globular domain protruding into the 
intermembrane space. Even if the precise role of COX11 in CcO assembly remain 
unknown, it is possible that copper transfer to and from COX11 occurs through 
heterodimeric interaction of a single COX11 subunit with copper chaperone COX17 
and COX1 CcO subunit respectively. Moreover is unclear if COX11 mediated copper 
incorporation occurs after CcO assembly or co-translationally, prior to the association 
of COX1 with other subunits. As COX11 is implicated in the assembly of the CuB site 
of CcO in yeast and a human homologue has been previously identified(10), this protein 
is a reasonable candidate for human CcO deficiency. 
For this reason I focus my work on COX11 in order to obtain the 155aa C-terminal 
soluble domain of  human COX11(Fig.2) and to characterize and solve the solution 
structure by NMR. 
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Fig.2: COX11 protein. A scheme of the protein. In my work I try to obtain the soluble C-
terminal globular domain excluding the transmembrane domain.  
 
 
 
4.2 Materials and methods 
 
The  DNA segment without the MSP of SURF1 (256aa) and the one of C-terminal 
soluble domain of human COX11 (155aa) were  amplified from cDNA by PCR. Two 
primers combination (with and without TEV site in the primers) were used to amplify 
the segments. Different polymerases and conditions were used to obtain the 
amplification:  
 
• Phusion Hot Start (BioLabs), +/- MgCl2, 60°C/64°C 
• KOD Polymerase(Novagen), +/- MgCl2, 60°C 
• Accuprime Pfx(Invitrogen), +/- MgSO4, +/- DMSO, 60°C 
 
The SURF1 gene amplification was obtained with KOD Polymerase, while the COX11 
gene amplification was obtained with Accuprime Pfx + MgSO4 + DMSO. 
Genes were cloned in the Gateway Entry vector  pDONR 221. SURF1 and COX11 
were then subcloned successfully into destination vectors through the Gateway LR 
reaction. Three different pDEST were used: pTH27, PMM (N-terminal 6-His tag) and 
pTH24 (C-terminal 6-His tag) which were prepared in Karolinska Institutet laboratories. 
Proteins were transformed in three different Escherichia coli  expression cells : Rosetta 
(DE3), BL21(DE3) and C41(DE3).   
All clones were grown simultaneously at two different temperatures (25°C and 37°C) 
and were lisated both with a native lysis buffer (Tris 20mM pH 8.0 + NaCl 100 mM + 
Lysozyme 1 mg/ml + Benzonase 10 U/ml) and with a buffer supplemented with FOS-
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 CHOLINE-12 (FC12- Anatrace) 1% as detergent. Proteins purification were done by 
ultracentrifugation using Nickel sepharose resin (Amersham) and the protein expression 
was checked by Dot-Blot with His-Probe-HRP(Pierce) and SDS-PAGE.  
SURF1 was solubilised using FC12 1% as detergent and lysate was purified using 
HisTrap chelating FF column. The His-tag was cleaved with TEV protease and removed 
using HisTrap chelating FF column again.  
The NMR sample were prepared using Phosphate buffer solution 20mM +NaCl 
100mM+FC12 0,1% at pH7.00. 
COX11 protein was expressed in inclusion bodies and pellet washed with Triton 1% 
were solubilised with Guanidine 6M. Dialysis with different concentration of Urea (4M, 
2M, 0M) and Arginine (0,5M, 0M) are performed follow one after the other, and then 
the protein was gel filtrated using Akta Prime plus with Superdex 75(GE Healthcare). 
The His-tag was cleaved with TEV protease and removed by gel filtration again. The 
NMR samples were prepared under reducing atmosphere in different  buffer conditions:   
 
? TrisHCl 50mM pH 8.0 + NaCl 100mM + DTT 10mM  
? Phosphate Buffer 50mM pH 7.0 + NaCl 100mM + DTT 10mM  
? BisTris 50mM pH 6.5 + NaCl 100mM + DTT 10mM  
 
The last condition was the best one even if  it presents precipitation. 
 
 
4.3 Results and discussion 
 
The first part of this project was carried out in Pär Nordlund’s Lab at the Karolinska 
Institutet in Stockholm, in order to perform High Throughput detection of different 
constructs and strains for both SURF1 and COX11 proteins. Moreover in Pär 
Nordlund’s research group I was able to use new modified plasmids (pTH27 and 
pTH24)  together with the commercial one in order to increase the probability to obtain 
proteins expression . We first amplify genes from a cDNA and clone them in different 
plasmids. After sequencing the constructs were transformed in different strains of 
E.Coli expression cells. We then proceed with the expression test. The use of 96-well 
plates allowed us to grow all the strains simultaneously and to perform an High 
Throughput screening. This kind of analysis is very useful in order to exploit an 
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 elevated number of different conditions (presence/absence of TEV cleavage site, 
different plasmids, three different strains, two different growth temperatures and two 
lysis buffer with/ without the addiction of detergent) for the expression of both COX11 
and SURF1 proteins. To detect the proteins expression, the cells were lysated both with 
a native lysis buffer and with a buffer with addiction of FC12 detergent. The lysates 
were successfully cleared from cell debris by ultracentrifugation of the 96-well plates. 
The next step was the His-tag purification  made by adding the Nickel sepharose resin 
to the lysates and by washing and eluting the proteins with different imidazol 
concentrations buffers. The presence of a 6-His tag in all constructs allowed us to detect 
the presence of both proteins by Dot-Blot using an anti His6 tag probe (Fig.3). 
 
37°C 25°C
Native Buffer
Detergent Buffer
Native Buffer
Detergent Buffer  
 
Fig.3: Dot-Blot screening. Highlighted circles show the best expression for SURF1 in 
blue and for COX11 in red. 
 
 
The Dot-Blot analysis showed that both COX11 and Surf1 proteins expressed at 37°C in 
the native and in the FC12 detergent buffers. At the contrary, at room temperature, only 
in FC12 detergent buffer we have protein expression. 
In particular, the best expression conditions (more  intense blot) for SURF1 protein 
were: 
? 37°C, Native buffer, no TEV site, pTH24, C41 cells 
? 37°C, Detergent buffer, with TEV site, pTH24, C41/BL21/Rosetta cells 
? 25°C, Detergent buffer, with TEV site, pTH24, C41/BL21/Rosetta cells 
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 The best expression conditions for COX11 protein were: 
? 37°C, Native buffer, with TEV site, pTH24, C41 cells 
? 37°C, Detergent buffer, with TEV site, pTH27, C41/Rosetta cells 
? 25°C, Detergent buffer, with TEV site, pTH27, C41/Rosetta cells 
 
The minor intensity of some blots showed in Fig.3 is often due to a less absorbance of 
the drop on the membrane rather than to differences in the protein expression yield. For 
this reason a more detailed analysis have to be carried out by SDS-PAGE of each blots 
(Fig.4). The latter analysis allowed to further restrict the number of expression 
conditions.  
 
We conclude that for SURF1 protein the best expression conditions were: 
 
? 37°C, Detergent Buffer, pTH24, C41/BL21/Rosetta cells with TEV site 
? 37°C, Detergent Buffer, pTH27, C41/Rosetta cells  without TEV site 
? 25°C, Detergent Buffer, pTH24, C41/BL21/Rosetta cells without TEV site 
 
For COX11 protein the best expression conditions were: 
 
? 37°C, Detergent Buffer, pTH24, C41 cells, with TEV site 
? 37°C, Detergent Buffer, pTH27 C41/Rosetta cells, with TEV site 
? 25°C, Detergent Buffer, pTH24, C41 cells, with/without TEV site 
 
 
The above conditions were subsequently used for the scale up of the coltures and 
expression optimization and purification were then carried out for both proteins. 
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Fig.4: SDS-PAGE. Gels show best expression conditions for SURF1 protein(in blue) 
and for COX11 protein (in red). 
 
 
4.3.1 SURF1 protein 
 
Scale up was done growing one liter colture  rich medium in flasks and the best 
construct results the  pTH24 in C41 expression cells. The expression growing colture 
has been performed at 18°C obtaining the higher yield (Fig.5). 
The cell debris was obtained  by centrifugation of the colture and then cells were 
disrupted by freeze-thaw lysis and sonication. Then, a first centrifugation (10 000 rpm, 
10 min) is necessary to remove the inclusion bodies and a second one (40 000 rpm, 45 
min) to isolate the membrane were SURF1 protein is located.  1% Fos-choline12 
(FC12) detergent buffer was used to solubilise the protein from the membrane with an 
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 SURF1 pTH24 C41  25°C
 
 
Fig. 5: Expression optimization. The gels show the increasing of 
expression  from colture growth at 25°C and  colture growth at 18°C. 
 
 
 
over night incubation at 4°C. The solubilised protein is then purified using HisTrap 
chelating column eluting the proteins with different imidazol concentrations buffers and 
 0.1% FC12. After cleavage with TEV enzyme, the protein was purified again with His-
Trap column keeping always 0.1%FC12 concentration. MALDI was then performed on 
a protein sample obtained directly cutting from an SDS-PAGE gel the band 
corresponding to the protein. The MALDI positive outcome showing 58.4% coverage of 
the peptides obtained from the sample by Trypsin digestion (Fig.6). 
In order to better characterize the protein and to check if the tertiary structure is well 
folded a 15N labelled sample was prepared in phosphate buffer 20mM pH7.00 + NaCl 
100mM + FC12 0.1%. The 1H-15N HSQC spectrum acquired at 900MHz spectrometer 
at 298K (Fig.7 A), shows the peaks are clustered in the range of 1H and 15N frequencies 
typical of unfolded protein. Unfortunately the increasing of temperature up to 310K did 
not improve the quality of 1H-15N HSQC (Fig.7 B). However both spectra shows the 
resonance typical of the side chain NHε1 of the Tryptophan (high lightened in red in 
Fig.7) suggesting that the protein is not completed unfolded  and that we can improve 
the quality of the spectrum increasing the amount of surfactant. The presence of these 
peaks suggest that some regions of the protein are folded. The detergent is necessary for 
the protein to be stable in solution, and up to now FC12 at 0.1% was the only detergent 
and concentration that we tested, but it appears evident that a detailed screening of 
different detergents concentrations is necessary. FC12 is indeed a very harsh detergent 
which can be useful for proteins solubilisation from the membranes, but it should be not 
the best detergent for NMR sample preparation. 
     SURF1 pTH24 C41 18°C 
   M     IB     Prot   FT1  FT2  W1  W2  W3  W4  W5  E1     E2   E3    M     IB      IB    Prot   FT1  FT2   W1    W2    W3    W4    E1     E2    E3 
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In order to obtain a good folded SURF1 protein  it will be interesting to screen different 
detergents (DHPC, DDM, LDAO, OG…) that will be tested at different levels of 
protein purification. First new detergents can replace FC12 completely starting from the 
beginning of the purification protocol and can be used to solubilise SURF1 protein from 
the membrane. Anyway in case no other detergents will be able to solubilise the protein, 
FC12 can be used only during solubilisation and than other detergents should be tested 
during the purification  protocol in the elution buffers. Moreover, it will be necessary to 
try different concentration of detergents in sample preparation preferably higher than 
0.1%. 
The right concentration should be tested easily adding the detergent directly in the NMR 
tube with SURF1 protein sample and acquiring an HSQC after each addition. Finally it 
will be  important to test also different pHs for  buffer. 
When the conditions will be optimized it will be very interesting to obtain the solution 
structure of SURF1 protein by NMR to better understand the relationship between the 
structure and the function of this membrane protein. Another important step should be 
also build SURF1 pathogenic mutants to better understand their role in CcO assembly 
process and how the mutations are involved in CcO-deficient Leigh syndrome. 
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 900 MHz      298K 15N
1H  
        A 
  
 
900 MHz      310K 15N
1H B 
 
 
 
Fig. 7: 1H-15N HSQC spectra at 900MHz of SURF1 protein. HSQC  was done at 
298K (A)and 310K(B) on SURF1 sample in Phosphate buffer 20mM pH7.00 + NaCl 
100mM + FC12 0,1%. NHε1 of tryptophan are high lightened in red. 
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 4.3.2 COX11 protein 
 
The scale up was done growing the constructs resulted positive in SDS-PAGE in one 
litre rich medium coltures in flasks. Cell debris obtained by centrifugation was disrupted 
by freeze-thaw lysis and sonication. Then the lisate was centrifuged at 40 000 rpm x 45’ 
in order to isolate inclusion bodies from soluble part. The soluble part was then purified 
using affinity His tag column and eluted with buffer with increasing imidazol 
concentration. SDS-PAGE gels showed that in all constructs, growth both at 37°C and 
25°C, COX11 was usually expressed in the inclusion bodies and no protein was 
detected in soluble part (In Fig.8A and Fig. 8B is shown the case of COX11 pTH27 
construct in C41 cells). In order to obtain a soluble expression of the protein the coltures 
were growth at lower temperature, exactly at 18°C and 4°C. Also in this case the protein 
was detected only in inclusion bodies as shown in SDS-PAGE gels in Fig. 8C and Fig. 
8D for COX11 pTH27 in C41 cells. 
 
 
 
 
D
COX11 pTH27 C41 25°C
M    IB Prot FT W1  W2  W3  E1   E2   E3
COX11 pTH27 C41 18°C
M    IB    Prot FT    W1  W2  W3  E1   E2   E3
COX11 pTH27 C41 4°C
IB  M Prot FT     W1   W2   W3  E1   E2   E3
COX11 pTH27 C41 37°C
M    IB    Prot FT    W1  W2    W3    E1    E2     E3 A B
C
 
 
Fig.8: SDS-PAGE gels show that COX11 is detected only in inclusion bodies at all 
tested temperatures (37°C in A; 25°C in B; 18°C in C; 4°C in D). 
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In order to extract the protein from inclusion bodies, refolding was performed. The 
inclusion bodies were first washed with Triton 1% and then solubilised with Guandine 
HCl 6M. The first approach was refolding by dilution, which is a  fast kind of refolding 
based on the rapid dilution of the concentrated protein. The solubilised concentrated 
protein was dropped slowly in a big amount of  buffer Tris HCl 200mM pH 8.0 + 
EDTA 10mM + DTT 10mM + L-Arginine 1M. The protein diluted was then 
concentrated and cleaved with TEV enzyme. After purification by His tag affinity 
column the Circular Dycroism (CD) was performed (Fig. 9)   
 
 
 
 
 
Fig. 9: CD spectra of  COX11 protein refolded by dilution. 
 
 
The Yang model shows a good fitting with 73% of β sheet, 18% of α helix and 9% of 
random coil. This data suggest that the protein presents an high content of secondary 
structure elements. In order to better characterized the protein, a COX11 sample was 
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 prepared using phosphate buffer solution 50mM pH7.00 + NaCl 100mM + DTT 5mM 
and 1D spectrum was acquired at 700MHz spectrometer at 298K (Fig. 10). 
 
700MHz      298 K
1H  
Fig. 10: 1D spectrum of COX11 refolded by dilution. 
 
 
The spectrum showed a reduced signal dispersion suggesting that the tertiary structure 
of the protein is not well folded. Moreover the sample presents high precipitation 
indicating that the protein is not stable.  
The second approach consisted in a slower refolding protocol where many dialysis were 
performed. In this case the solubilised inclusion bodies were dialysed several times in 
buffers with decreasing concentration of urea (4M, 2M and 0M) and increasing 
concentration of L-Arginine (0.3M and 0.5M) which is necessary for protein refolding. 
During dialysis we observed slightly protein precipitation. Therefore a gel filtration was 
necessary to remove impurities and  not folded protein (Fig. 11). The chromatogram 
shows a big amount of protein (higher peak) isolated from the impurity (lower peaks). 
The protein was cleaved subsequently with TEV enzyme and gel filtrated again to 
remove the His6 tag. We carry out a CD spectrum which gives 66 % of β sheet, 13% of 
α helix and 21% of random coil suggesting an high content of secondary structure 
elements (Fig.12). 15N labelled sample was prepared in TrisHCl 50mM pH 8.0 + NaCl 
100mM + DTT 10mM and 1H-15N HSQC spectrum was acquired at 700MHz 
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 spectrometer and 298K(Fig.13). The spectrum shows that the protein was folded but we 
counted a lower number of amide signals than expected. 
 
Different samples conditions were tried to improve signal dispersion and to increase the 
number of signals in the 1H-15N HSQC spectrum(Fig.14, Fig.15). We observed that the 
best results has been obtained with BisTris 50mM pH 6.5 + NaCl 100mM + DTT 
10mM (Fig.16). In spite of the high protein instability we acquired the triple resonances 
experiments necessary for backbone assignment. 
Therefore we are now working to improve sample stability and we are trying to produce 
other two constructs of COX11 protein: one without the His6 tag, which is no more 
necessary in case of refolding protocol; the other construct is a short one modelled on 
the sequence of  COX11 homolog from Sinorhizobium meliloti, which presents 47.5% 
of identity as calculated with LALIGN program 
(http://www.ch.embnet.org/software/LALIGN_form.html) (Fig.17).  
After the optimization of sample stability it will be interesting to solve the solution 
structure of COX11 because of  it will help to better understand protein function. 
Interesting  perspectives will be build COX11 cysteines mutants to understand how it 
binds Cu(I) ions and, consequently, how it is involved in the assembly of copper centre 
of CcO protein. Moreover it will be useful to study the interactions between COX11 and 
COX17 to understand how latter protein release Cu(I) ions to COX11 protein.
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Fig.11: Gel filtration chromatogram of COX11 refolded by dialysis. 
 
 
 
 
Fig.12: CD spectrum of  COX11 protein refolded by dialysis. 
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1H
15N
1H 15N HSQC
 
 
Fig.13: 1H-15N HSQC  spectrum at 700MHz, 298K of  COX11 protein. 
The sample is prepared in TrisHCl 50mM pH 8.0 + NaCl 100mM + 
DTT 10mM. 
 
 
 
1H
15N1H 15N HSQC
 
 
 
Fig.14: 1H-15N HSQC  spectrum at 700MHz, 298K of  COX11 protein. 
The sample is prepared in Phosphate Buffer 50mM pH 7.0 + 
NaCl 100mM + DTT 10mM. 
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1H
15N
1H 15N HSQC
 
 
Fig.15: 1H-15N HSQC  spectrum at 700MHz, 298K of  COX11 protein. 
The sample is prepared in BisTris 50mM pH 6.5 + 
 NaCl 100mM + DTT 10mM. 
 
 
 
1H
15N
1H 15N HSQC
 
 
 
Fig.16: Overlapping of 1H-15N HSQC  spectrum of  COX11 protein 
in TrisHCl 50mM pH 8.0 + NaCl 100mM +DTT 10mM (red) and spectrum 
in BisTris 50mM pH 6.5 + NaCl 100mM + DTT 10mM (blue).  
Both spectra are acquired at  700MHz, 298K. 
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Comparison of: 
(A) ./wwwtmp/.15325.1.seq meliloti 144 bp                                    
- 144 aa 
(B) ./wwwtmp/.15325.2.seq human 155 bp                                       
- 155 aa 
 using matrix file: BL50 (15/-5), gap-open/ext: -14/-4 E(limit)   0.05 
 
  47.5% identity in 118 aa overlap (8-125:24-141); score:  397 
E(10000): 1.6e-33 
 
        10        20        30        40        50        60        
melilo ILDEKIKVTFDANVAAGLPWEFVPVQRDIDVRIGETVQIMYRAKNLASTPTTGQATFNVT 
       . :. ::..:.:.: :.: :.: : : .: :  :::.  .::::: .. :. : .:.:.. 
human  VKDRIIKISFNADVHASLQWNFRPQQTEIYVVPGETALAFYRAKNPTDKPVIGISTYNIV 
            30        40        50        60        70        80    
 
        70        80        90       100       110       120      
melilo PMAAGAYFNKVQCFCFTETTLEPGEEMEMPVVFFVDPEIVKPVETQGIKTLTLSYTFY 
       :. :: ::::.::::: :  :.: ::..::: :..:::...  .   .  .::::::. 
human  PFEAGQYFNKIQCFCFEEQRLNPQEEVDMPVFFYIDPEFAEDPRMIKVDLITLSYTFF 
90       100       110       120       130 
 
 
 
Fig.17: comparison of Sinorhizobium meliloti COX11 sequence and Human COX11 
sequence looking for local similarities using LALIGN program. 
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Chapter 5 
 
Familial Amyotrophic Lateral Sclerosis 
Expression and characterization of  
human CCS protein 
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 5.1 Introduction 
 
 
Familial Amyotrophic Lateral Sclerosis (FALS) is a motor neuron disease characterized 
by  a progressive muscle weakness and atrophy. 5 to 10% of all cases of Amyotrophic 
Lateral Sclerosis (ALS) are constituted by familial cases (FALS) which are inherited in 
a dominant manner (1, 2). Each FALS type is characterized by mutation in a specific 
gene. In particular, type 1, is caused by autosomal dominant mutations in the gene 
SOD1, that encodes copper zinc superoxide dismutase protein (SOD1)(3). The latter is 
an antioxidant enzyme found in the cytosol, nucleus, peroxisomes, and mitochondrial 
intermembrane space of eukaryotic cells (4-6). The human enzyme is a 32-kDa 
homodimer, with one copper- and one zinc-binding site per 153-amino acid subunit and 
an intrasubunit disulfide bond. The dimer interface  is stabilized by numerous main-
chain to main-chain hydrogen bonds, water-mediated hydrogen bonds, and hydrophobic 
contacts (7, 8).  
The metallation of the SOD1 polypeptide is aided by CCS (copper chaperone for 
SOD1) (9, 10). CCS, which is able to bind copper ions and one zinc ion, is implicated in 
the insertion of the copper co-factor and in the formation of the disulfide bond during 
insertion of copper into SOD1 in yeast(11). CCS protein is ubiquitously expressed in all 
human tissues and presents three functional distinct domains (Fig.1): the N-terminal 
domain is homologous to ATX1 copper chaperone with a MXCXXC copper binding 
motif (12); the second domain has a high homology to SOD1 and is able to recognize 
the SOD1 protein allowing copper transfer (13). The last domain presents a CXC motif 
able to bind copper(14). This domain, that results disordered in the crystal structure of 
yeast CCS(13), is crucial for SOD1 activation. It has been hypothesized that domain III 
lies near domain I and together then insert copper  in SOD’s site (14).  
Yeast mutants lacking CCS express an apo form of SOD1 protein without copper ions 
(15) and mice with disruptions in CCS gene exhibit marked reductions in SOD1 activity 
(16). Moreover CCS has been implicated in SOD1-related FALS disease showing 
SOD1 gene missense mutation along all protein sequence. Indeed an altered maturation 
of SOD1 mutants can be due to incorrect copper insertion or disulfide formation CCS-
mediated processes. 
The aim of this work was to obtain the full length CCS protein in order to characterize 
the solution structure, to analyze its copper binding properties and the mechanism of 
copper transfer to copper depleted ZnSOD1. 
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36aa (activation)85aa (ATX1 like) 153aa (SOD like)
DOMAIN 1                                                   DOMIN 2                                     DOMAIN 3  
 
Fig.1: A scheme of the three domains of CCS protein. 
 
 
5.2 Materials and methods 
 
The  DNA segment  of  full length human CCS (274aa) were  amplified from cDNA by 
PCR. Primers with C-terminal TEV site or with N-terminal TEV site or without TEV 
site were used with different kind of  polymerase :  
• Phusion Hot Start (BioLabs), +/- MgCl2, 60°C/64°C 
• KOD Polymerase(Novagen), +/- MgCl2, 60°C 
• Accuprime Pfx(Invitrogen), +/- MgSO4, +/- DMSO, 60°C 
Using the latter with MgSO4 and the Touchdown Polymerase chain reaction was 
obtained a good amplification of  the CCS DNA segment. The latter was then cloned in 
the Gateway Entry vector  pDONR 221 by BP Gateway reaction and then  subcloned 
with LR Gateway reaction in pTH27, PMM (N-terminal 6-His tag) and pTH24  (C-
terminal 6-His tag) plasmids. The best expression was observed with the construct 
containing the TEV site in pTH27 plasmid transformed in BL21(DE3) Codon Plus 
expression cells. Scale up colture was done using fermentors (Inforce) at 25°C. The 
expression was induced by 0.7mM IPTG and ZnSO4 1mM was added after one hour 
directly in the colture. Cells were disrupted by sonication and the protein  was purified 
using Nickel sepharose resin (Amersham). The His-tag was cleaved with TEV protease 
and removed using HisTrap chelating column. 
NMR sample was prepared with different buffers in order to optimize sample 
conditions: 
? Phosphate Buffer 50mM pH 7.0 
? Bis Tris 50mM pH 6.5 
? Bis Tris 50mM+ 5mM EDTA pH 6.5 
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 The  DNA segment  of  the first two domains of CCS protein (238aa) was also 
amplified by PCR using TAQ polymerase (Invitrogen). The obtained fragments were 
then cloned in the Gateway Entry vector pENTR /TEV/D-TOPO to include the TEV 
protease cleavage site at the N-terminal end. The segments were finally subcloned into 
destination vector  pTH34 (GB1 tag) through the Gateway LR reaction and plasmid 
expressing the protein His-tagged at the N-terminus in Origami pLysS expression cells 
were selected. The scale up was done growing colture in rich medium flasks at 37°C. 
0.5mM IPTG was used for induction and ZnSO4 1mM was added after one hour directly 
in the colture. Cell debris was disrupted by sonication and the protein was purified using 
Nickel sepharose resin (Amersham). The protein was cleaved with TEV enzyme to 
remove His6 and GB1 tag and purified with HisTrap chelating column. 15N labelled 
samples of full length and two domains constructs were prepared growing colture in 
minimum medium with the addiction of glycerol 50%. Bis Tris 50mM pH 6.5 and Bis 
Tris 50mM+ 5mM EDTA pH 6.5 were the selected buffer for sample preparation. 
 
5.3 Results and discussion 
 
Amplification of the DNA segment of the full length CCS protein was obtained by 
PCR. Different kind of polymerase were tested in order to obtain the amplification 
because of the length of the primers necessary to perform the BP Gateway reaction. The 
gene was amplified with Accuprime Pfx (Invitrogen) with MgSO4  using a particular 
kind of PCR, Touchdown Polymerase chain reaction, during which the annealing 
temperature is decreased in increments for every subsequent set of cycles, in order to 
start with not very specific amplification and to obtain at the end of the PCR only 
specific amplifications. These amplified genes were cloned in the Gateway Entry vector  
pDONR 221 by BP Gateway reaction, in order to subclone  all in different destination 
vectors (pTH27, PMM and  pTH24) which were prepared in Karolinska Institutet 
laboratories and kindly made available from Pär Nordlund’s group. Different kind of 
expression cells were then tested resulting pTH27 construct in BL21(DE3) Codon Plus 
cells as the one with high expression levels of CCS protein. The scale up was done 
growing an over night colture in fermentors at 25°C. Cells obtained by centrifugation 
were disrupted by sonication and the soluble part was isolated from inclusion bodies by 
ultracentrifugation. The protein was binded to Nickel sepharose resin (Amersham) by 
one hour agitation in cold room and then eluted from the packed resin using different 
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 imidazol concentrations buffers. After cleavage with TEV enzyme the His6 tag was 
removed using HisTrap chelating column (Fig.2). A gel filtration was performed using 
Superdex 75 to further  purification of the sample and the chromatogram shows the 
presence of one form of CCS protein (Fig.3).  
 
 
M      L       IB     FT      W1    W2     W3
 
 
Fig. 2: SDS-PAGE of CCS protein purified after TEV cleavage. 
 
 
 
CCS
 
 
Fig.3: Gel filtration chromatogram of CCS full length protein. 
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 To detect if it is a monomer (29040 Da) or a dimer (58080 Da) Light Scattering was 
performed clearly demonstrating that the CCS protein is in the dimeric form (Fig.4).  
 
 
 
 
 
Fig.4: Light Scattering spectrum shows that CCS is in a dimeric form. 
 
 
 
Atomic Absorption spectroscopy was then performed  for determining the concentration 
of metals in a sample, with the result of  100%  Zn and less than 5% Cu. 
ESI mass spectrometry also shows a main peak of dimeric forms and a minor peak of 
the monomeric form with major mass, corresponding to CCS (theoretical) + 1Zn + 1Cu.  
ESI mass was also done in acidic conditions showing two or more protein forms, with 
different molecular masses, where the major form is CCS - 1 Zn - 1 Cu. This result 
shows that two metal ions (one Zn and one Cu) are bound to each monomer subunit of 
CCS in the sample. Addition of Cu(I) does not lead to appearance of additional metal 
ion binding by ESI mass spectrometry, which suggests that protein is saturated with 
metal ions.  
Titration of CCS + Cu sample with DTT reveals dissociation of one Cu ion at around 7 
mM DTT, thus resulting an affinity of 2.4 fM. Only Cu(I) ion is dissociated in these 
conditions, whereas the Zn ion remains to be bound to CCS (Fig.5).  
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Fig.5: a) ESI mass spectra repeated during titration of CCS full length sample with 
DTT show the increasing amount of apo form of CCS. b) Fitting of the affinity affinity 
between CCS and Cu(I). The graph shows the relation between the CCs-Cu(I) complex 
and the formation of free Cu(I) due to the presence of DTT. 
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 Apparently it needs higher concentration of DTT but at higher than 30 mM 
concentrations of DTT peaks, which are not very intensive, disappear. CCS has high 
molecular weight and it is not seen as proteins with lower molecular weights. From the 
data anyway it does not follow from which domain of CCS metal is dissociated.  
To better characterize the structural properties of CCS protein a 15N labelled sample was 
prepared in Phosphate Buffer 50mM pH 7.0 and 1H-15N HSQC spectrum was acquired 
at 500MHz  spectrometer at 310 K (Fig.6). Several cross-peaks have resonances typical 
of folded protein, but their number are less than expected for a protein of 238aa. 
Moreover several cross-peaks are found in the typical spectral region of unfolded 
proteins. Therefore we try to optimize the sample conditions changing pH and buffer 
condition. The NMR sample was prepared in  Bis Tris 50mM pH 6.5 and  the 1H-15N 
HSQC was acquired at 900MHz spectrometer both at  298K (Fig. 7) and 310K (Fig.8). 
The spectra show that cross-peaks are sharper at pH 6.5 and at 310K thus obtaining an 
improvement in the number of peaks. In particular we can detect a cross-peak 
corresponding to the typical SOD1 domain Glycine residue. A futher improvement was 
obtained adding 5mM EDTA directly in the NMR tube of CCS sample. Indeed, 1H-15N 
HSQC performed at 900MHz and at 310K shows a large increment in cross-peaks 
number (Fig.9).   
 
 
1H
1H 15N HSQC15N
 
Fig.6: 1H-15N HSQC  spectrum at 500MHz, 310K of  CCS protein. 
The sample is prepared in Phosphate Buffer 50mM pH 7.0. 
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1H
1H 15N TROSY15N
 
 
Fig.7: 1H-15N HSQC  spectrum at 900MHz, 298K of  CCS protein. 
The sample is prepared in Bis Tris 50mM pH 6.5. 
 
 
 
 
 
 
1H
1H 15N TROSY15N
 
Fig.8: 1H-15N HSQC  spectrum at 900MHz, 310K of  CCS protein. 
The sample is prepared in Bis Tris 50mM pH 6.5. In red is high lightened  
a Glycine typical of SOD spectrum. 
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Fig. 9: 1H-15N HSQC  spectrum at 900MHz, 310K of  CCS protein. 
The sample is prepared in Bis Tris 50mM pH 6.5+5mM EDTA 
 
 
 
 
Anyway a part of the protein still remains  unfolded. Since it is known that in the crystal 
structure of CCS the third domain is disordered, we hypothesized that the unfolded part 
observed in the 1H-15N HSQC map should belong to this domain. For that reason we 
study a short construct of CCS protein comprehensive only the first two folded domains 
(CCS1-2). The 238aa long gene segment was amplified by PCR and cloned with 
TOPO-TEV reaction in pENTR/TEV/D-TOPO plasmid. Using the LR gateway reaction 
the gene was then subcloned in different destination plasmids and transformed in 
different strains. CCS1-2 construct in pTH34 expression plasmid (characterized by a 
GB1 tag) transformed in Origami pLysS expression cells was the only one showing 
high soluble expression levels. Cells were disrupted by sonication and purification was 
performed using Nickel sepharose resin. Protein eluted from the packed resin using 
different imidazol concentrations was cleavage with TEV enzyme and the protein was 
finally purified using HisTrap chelating column. ESI Mass Spectrometry on the protein 
gave the right weight  of the protein (25114Da). Gel filtration analysis show only one 
peak corresponding to the dimeric protein state as proved by light scattering analysis.  
1H-15N HSQC spectra in BisTris 50mM pH6.5 were performed at 900MHz  
spectrometer at different temperatures: 285K(Fig.10), 298K(Fig.11) and 310K(Fig.12). 
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 Frome the analysis of the spectra we can conclude that at higher temperatures the 
number of cross-peaks improves a lot; at 285K only few cross-peaks belonging to 
unstructured protein segment can be detected, wile the cross-peaks number increases at 
298K and even more in the one at 310K, in which again the typical SOD domain like 
Gycine was observed(Fig.13). As already tested for the full length construct we 
obtained a further improvement by adding 5mM EDTA in the sample. The 1H-15N 
HSQC spectrum performed at 900MHz spectrometer at 310K is overlapped with the 
one without EDTA and it clearly  shows an increasing number of amide signals 
(Fig.14). 
After sample optimization of both construct we are now producing 2H13C15N labelled 
sample for acquisition of triple resonance experiments for the assignment with the final 
goal of solving the full length solution structure of human CCS protein. The triple 
labelled sample of CCS 1-2 will be done to facilitate the backbone resonance 
assignment. It will be interesting to study the interaction between CCS and copper and 
to build cysteines residues mutants to  understand in detail the functions of the three 
domains. Moreover these data will be necessary to study the interaction of CCS with 
SOD1 protein to characterize at the molecular level how CCS is involved in SOD1 
maturation.   
  
1H
15N
1H 15N HSQC
 
 
Fig.10: 1H-15N HSQC  spectrum at 900MHz, 285K of  CCS1-2 protein. 
The sample is prepared in Bis Tris 50mM pH 6.5. 
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Fig.11: 1H-15N HSQC  spectrum at 900MHz, 298K of  CCS1-2 protein. 
The sample is prepared in Bis Tris 50mM pH 6.5. 
 
 
 
1H
15N
1H 15N HSQC
 
Fig.12: 1H-15N HSQC  spectrum at 900MHz, 310K of  CCS1-2 protein. 
The sample is prepared in Bis Tris 50mM pH 6.5. 
   In red is high lightened a Glycine typical of SOD spectrum. 
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Fig.13: Overlapping of 1H-15N HSQC  spectrum of  CCS1-2 protein 
in BisTris 50mM pH 6.5 at 298K (red) and the one at 310K (green). 
Both spectra are acquired at  900MHz spectrometer. 
1H
1H 15N HSQC
15N
 
 
Fig.14: Overlapping of 1H-15N HSQC  spectrum of  CCS1-2 protein 
in BisTris 50mM pH 6.5 (red) and the spectrum of the sample with the  
addiction of 5mM EDTA (green). Both spectra are acquired at  900MHz 
spectrometer, at 310K. 
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 Summary and perspectives 
 
 
Information about the three dimensional structure of biological macromolecules as 
proteins is vital for understanding their function at the molecular level. The role of 
structural biology has become increasingly important in many fields of the life science 
and has gained great importance also in drug design. NMR and X-ray crystallography 
are the methods used to obtain 3D structures of macromolecules. In particular 
biomolecular NMR spectroscopy is the most important method to obtain information at 
the atomic level in solution, providing not only structural data but also information 
about conformational dynamics and exchange processes, internal mobility and 
dynamics of biomolecules at timescales ranging from picoseconds to seconds. NMR is 
very efficient in mapping interactions with other molecules, e.g. protein/protein, 
protein/nucleic acid, protein/metal ions or ligand interactions. Furthermore it should be 
kept in mind that a large majority of the functional processes in the cell occurs through 
weak transient interactions among proteins (interactome). Unfortunately, the 
characterization at the atomic level of the weak interactions is difficult, due to their 
dynamic nature. NMR is the more appropriate technique to characterize these weak 
protein-protein interaction processes and it is very efficient in mapping interaction 
surfaces of protein/protein complexes. 
Anyway, biophysical investigations of macromolecules usually rely on the availability 
of a purified and stable protein samples. In fact, an inhomogeneous preparation and/or 
aggregation of the protein target may severely compromise its structural 
characterization. The first step to perform an NMR study therefore involves 
optimization of the measurement conditions as pH, ionic strength, and temperature that 
can more appropriately be adjusted to mimic physiological conditions. Furthermore, in 
the case of membrane proteins, which I have produced during my PhD work, the choice 
of detergent and the path by which the protein is transferred from organic solvents into 
detergent micelles can greatly affect the structure and aggregation state of the 
transmembrane domains, and hence their suitability for NMR structure determination. 
During my PhD studies, I acquired knowledge on the production and purification of 
membrane proteins; in particular, my stay at the Karolinska Institutet in Stockholm 
allowed me to approach advanced high-throughput techniques in gene cloning and in 
the handling of membrane proteins. 
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 In this PhD work I was involved in the production of four different proteins implicated 
in rare diseases. Different protocols were used on the basis of their features in order to 
obtain proper quantity and purity necessary for NMR characterization of them.  
The first protein I have studied is the Wilson protein (ATP7B), an important human 
copper(I)-transporting P-type ATPase involved in copper-regulated trafficking between 
the trans-Golgi network (TGN)  and plasma membranes. Mutation in the gene ATP7B 
give rise to Wilson disease (WD) which is an autosomal recessive copper toxicosis 
condition. 
The N-terminal tail of ATP7B protein  was obtained to study the behaviour of the six 
metal binding domains in presence of Cu(I) and Cu(I)-HAH1 complex in order to  
understand the functional role of the N-terminal tail in copper trafficking and in Wilson 
disease. Moreover a short construct comprehensive of the first two domains of the 
protein and a cysteines mutated ATP7B protein were obtained for further analysis by 
which we conclude that domains 1, 2 and 4 form an intermolecular Cu(I)-bridged 
adduct with HAH1, while domains 3, 5 and 6 remove Cu(I) from the metallochaperone 
HAH1 independently from the adduct formation. 
SURF1 and COX11 proteins were studied in order to understand their role in CcO 
assembly mechanism. SURF1 membrane protein was solubilised with FC12 detergent 
and high  purification was obtained even if NMR spectrum suggest that screening of 
different detergents and concentrations are necessary to obtained a folded protein. The 
resolution of SURF1 protein structure should be the starting point to study how it is 
involved in CcO assembly process. Moreover build SURF1 mutants should help to 
obtain information about their role in Leigh syndrome.  
High yield of C-terminal soluble part of COX11 protein was obtained  using refolding 
protocol and  nice NMR spectra were obtained. The solution structure of COX11 will be 
then solved and its copper binding properties characterized in order to understand how 
COX11 is involved in assembly of copper centers of CcO protein. In this frame 
interaction studies by NMR between COX11 and COX17 chaperone will be carried out. 
The last project was focussed on the role of the human copper chaperone of superoxide 
dismutase(CCS) in FALS disease. Full length and short constructs of CCS were 
obtained and characterized by CD and NMR. Both protein constructs are nicely folded 
and we are therefore preparing triple labelled NMR samples in order to solve the 
solution structure and to use it as starting point to study interactions with SOD1 protein 
and with Cu(I) ions. 
 
 106
  107
 
Production and structural characterization of these proteins will be the starting point to 
understand the mechanisms by which all these proteins act and are involved in different 
cellular mechanisms and in the respective diseases. Moreover, the syndromes here 
studied are rare diseases and these data should be the hint for new studies in drug 
discovery. 
 
 
 
 
 
 
